Background  ||| S:24 E:52 ||| NN
Bacillus  ||| S:52 E:61 ||| NN
thuringiensis  ||| S:61 E:75 ||| NNS
( ||| S:75 E:76 ||| -LRB-
Bt ||| S:76 E:78 ||| NNP
)  ||| S:78 E:80 ||| -RRB-
has  ||| S:80 E:84 ||| VBZ
been  ||| S:84 E:97 ||| VBN
sold  ||| S:97 E:102 ||| VBN
commericially  ||| S:102 E:116 ||| NNS
and  ||| S:116 E:120 ||| CC
used  ||| S:120 E:125 ||| VBN
as  ||| S:125 E:128 ||| IN
a  ||| S:128 E:130 ||| DT
biopesticide  ||| S:130 E:143 ||| JJ
worldwide  ||| S:143 E:153 ||| NN
for  ||| S:153 E:165 ||| IN
over  ||| S:165 E:170 ||| IN
half  ||| S:170 E:175 ||| PDT
a  ||| S:175 E:177 ||| DT
century ||| S:177 E:184 ||| NN
.  ||| S:184 E:186 ||| .
However ||| S:186 E:193 ||| RB
,  ||| S:193 E:195 ||| ,
growing  ||| S:195 E:203 ||| VBG
public  ||| S:203 E:210 ||| JJ
concern  ||| S:210 E:226 ||| NN
surrounding  ||| S:226 E:238 ||| VBG
Bt  ||| S:238 E:241 ||| JJ
use  ||| S:241 E:245 ||| NN
has  ||| S:245 E:249 ||| VBZ
sparked  ||| S:249 E:257 ||| VBN
worldwide  ||| S:257 E:267 ||| JJ
debate  ||| S:267 E:274 ||| NN
over  ||| S:274 E:287 ||| IN
current  ||| S:287 E:295 ||| JJ
policies  ||| S:295 E:304 ||| NNS
[  ||| S:304 E:306 ||| -LRB-
1  ||| S:306 E:308 ||| LS
]  ||| S:308 E:310 ||| -RRB-
.  ||| S:310 E:312 ||| .
For  ||| S:312 E:316 ||| IN
example ||| S:316 E:323 ||| NN
,  ||| S:323 E:325 ||| ,
in  ||| S:325 E:328 ||| IN
India ||| S:328 E:333 ||| NNP
,  ||| S:333 E:335 ||| ,
fear  ||| S:335 E:340 ||| NN
over  ||| S:340 E:345 ||| IN
a  ||| S:345 E:355 ||| DT
potential  ||| S:355 E:374 ||| JJ
Bombyx  ||| S:374 E:381 ||| JJ
mori  ||| S:381 E:386 ||| NNS
( ||| S:386 E:387 ||| -LRB-
silkworm ||| S:387 E:395 ||| LS
)  ||| S:395 E:397 ||| -RRB-
epizootic ||| S:397 E:406 ||| NN
,  ||| S:406 E:408 ||| ,
or  ||| S:408 E:419 ||| CC
microbial  ||| S:419 E:429 ||| JJ
pathogen  ||| S:429 E:438 ||| JJ
outbreak ||| S:438 E:446 ||| NN
,  ||| S:446 E:448 ||| ,
inspired  ||| S:448 E:457 ||| VBD
a  ||| S:457 E:459 ||| DT
governmental  ||| S:459 E:472 ||| JJ
ban  ||| S:472 E:476 ||| NN
on  ||| S:476 E:487 ||| IN
the  ||| S:487 E:491 ||| DT
use  ||| S:491 E:495 ||| NN
of  ||| S:495 E:498 ||| IN
Bt ||| S:498 E:500 ||| NNP
,  ||| S:500 E:502 ||| ,
despite  ||| S:502 E:510 ||| IN
the  ||| S:510 E:514 ||| DT
nation ||| S:514 E:520 ||| NN
's  ||| S:520 E:523 ||| POS
continuing  ||| S:523 E:534 ||| JJ
use  ||| S:534 E:538 ||| NN
of  ||| S:538 E:549 ||| IN
traditional  ||| S:549 E:561 ||| JJ
chemical  ||| S:561 E:570 ||| NN
pesticides  ||| S:570 E:581 ||| NNS
[  ||| S:581 E:583 ||| -LRB-
2  ||| S:583 E:585 ||| LS
]  ||| S:585 E:587 ||| -RRB-
.  ||| S:587 E:597 ||| .
While  ||| S:597 E:603 ||| IN
pest  ||| S:603 E:608 ||| JJ
control  ||| S:608 E:616 ||| NN
with  ||| S:616 E:621 ||| IN
Cry  ||| S:621 E:625 ||| NNP
toxins  ||| S:625 E:632 ||| NN
that  ||| S:632 E:637 ||| WDT
possess  ||| S:637 E:645 ||| VBP
low  ||| S:645 E:658 ||| JJ
B.  ||| S:658 E:661 ||| NNP
mori  ||| S:661 E:666 ||| JJ
activity  ||| S:666 E:675 ||| NN
(  ||| S:675 E:686 ||| -LRB-
i.e  ||| S:686 E:690 ||| NNP
.  ||| S:690 E:692 ||| .
Cry1Ac ||| S:692 E:698 ||| NNP
)  ||| S:698 E:700 ||| -RRB-
is  ||| S:700 E:703 ||| VBZ
a  ||| S:703 E:705 ||| DT
viable  ||| S:705 E:712 ||| JJ
solution  ||| S:712 E:721 ||| NN
in  ||| S:721 E:732 ||| IN
affected  ||| S:732 E:741 ||| JJ
countries ||| S:741 E:750 ||| NNS
,  ||| S:750 E:752 ||| ,
it  ||| S:752 E:755 ||| PRP
is  ||| S:755 E:758 ||| VBZ
worthwhile  ||| S:758 E:769 ||| VBN
to  ||| S:769 E:772 ||| TO
investigate  ||| S:772 E:784 ||| VB
the  ||| S:784 E:796 ||| DT
specific  ||| S:796 E:805 ||| JJ
molecular  ||| S:805 E:815 ||| JJ
mechanisms  ||| S:815 E:826 ||| NNS
that  ||| S:826 E:831 ||| WDT
make  ||| S:831 E:836 ||| VBP
Cry1Aa  ||| S:836 E:843 ||| RB
highly  ||| S:843 E:858 ||| RB
active ||| S:858 E:864 ||| JJ
.  ||| S:864 E:866 ||| .
Early  ||| S:866 E:872 ||| JJ
work  ||| S:872 E:877 ||| NN
took  ||| S:877 E:882 ||| VBD
advantage  ||| S:882 E:892 ||| NN
of  ||| S:892 E:895 ||| IN
the  ||| S:895 E:899 ||| DT
fact  ||| S:899 E:904 ||| NN
that  ||| S:904 E:909 ||| IN
Cry1Aa ||| S:909 E:915 ||| NNP
,  ||| S:915 E:925 ||| ,
but  ||| S:925 E:929 ||| CC
not  ||| S:929 E:933 ||| RB
Cry1Ac ||| S:933 E:939 ||| CD
,  ||| S:939 E:941 ||| ,
is  ||| S:941 E:944 ||| VBZ
toxic  ||| S:944 E:950 ||| JJ
to  ||| S:950 E:962 ||| TO
B.  ||| S:962 E:965 ||| NNP
mori  ||| S:965 E:970 ||| NN
.  ||| S:970 E:972 ||| .
For  ||| S:972 E:976 ||| IN
example ||| S:976 E:983 ||| NN
,  ||| S:983 E:985 ||| ,
Ge  ||| S:985 E:997 ||| FW
et  ||| S:997 E:1000 ||| FW
al.  ||| S:1000 E:1004 ||| FW
[  ||| S:1004 E:1006 ||| -LRB-
3  ||| S:1006 E:1008 ||| LS
]  ||| S:1008 E:1010 ||| -RRB-
exchanged  ||| S:1010 E:1020 ||| VBD
hypervariable  ||| S:1020 E:1042 ||| JJ
regions  ||| S:1042 E:1050 ||| NNS
between  ||| S:1050 E:1058 ||| IN
genes  ||| S:1058 E:1064 ||| NNS
encoding  ||| S:1064 E:1073 ||| VBP
the  ||| S:1073 E:1077 ||| DT
two  ||| S:1077 E:1081 ||| CD
toxins  ||| S:1081 E:1088 ||| NNS
and  ||| S:1088 E:1092 ||| CC
localized  ||| S:1092 E:1110 ||| VBN
the  ||| S:1110 E:1114 ||| DT
toxicity  ||| S:1114 E:1123 ||| JJ
specifying  ||| S:1123 E:1134 ||| JJ
region  ||| S:1134 E:1141 ||| NN
of  ||| S:1141 E:1144 ||| IN
Cry1Aa  ||| S:1144 E:1151 ||| CD
to  ||| S:1151 E:1154 ||| TO
residues  ||| S:1154 E:1171 ||| CD
332-450  ||| S:1171 E:1179 ||| CD
in  ||| S:1179 E:1182 ||| IN
domain  ||| S:1182 E:1189 ||| JJ
II ||| S:1189 E:1191 ||| NNP
.  ||| S:1191 E:1193 ||| .
A  ||| S:1193 E:1195 ||| DT
follow-up  ||| S:1195 E:1205 ||| JJ
study  ||| S:1205 E:1211 ||| NN
demonstrated  ||| S:1211 E:1224 ||| VBD
the  ||| S:1224 E:1236 ||| DT
toxicity  ||| S:1236 E:1245 ||| JJ
specifying  ||| S:1245 E:1256 ||| JJ
residues  ||| S:1256 E:1265 ||| NNS
were  ||| S:1265 E:1270 ||| VBD
involved  ||| S:1270 E:1279 ||| VBN
in  ||| S:1279 E:1282 ||| IN
binding  ||| S:1282 E:1299 ||| JJ
B.  ||| S:1299 E:1302 ||| NNP
mori  ||| S:1302 E:1307 ||| FW
brush  ||| S:1307 E:1313 ||| FW
border  ||| S:1313 E:1320 ||| FW
membrane  ||| S:1320 E:1337 ||| FW
vesicles  ||| S:1337 E:1346 ||| FW
[  ||| S:1346 E:1348 ||| -LRB-
4  ||| S:1348 E:1350 ||| LS
]  ||| S:1350 E:1352 ||| -RRB-
.  ||| S:1352 E:1354 ||| .
More  ||| S:1354 E:1359 ||| RBR
specifically ||| S:1359 E:1371 ||| RB
,  ||| S:1371 E:1373 ||| ,
alanine  ||| S:1373 E:1381 ||| JJ
substitution  ||| S:1381 E:1394 ||| NN
or  ||| S:1394 E:1405 ||| CC
deletion  ||| S:1405 E:1414 ||| NN
of  ||| S:1414 E:1417 ||| IN
residues  ||| S:1417 E:1426 ||| CD
365  ||| S:1426 E:1430 ||| CD
to  ||| S:1430 E:1433 ||| TO
371  ||| S:1433 E:1437 ||| CD
removed  ||| S:1437 E:1445 ||| VBN
nearly  ||| S:1445 E:1452 ||| RB
all  ||| S:1452 E:1456 ||| DT
toxicity  ||| S:1456 E:1473 ||| NN
and  ||| S:1473 E:1477 ||| CC
binding  ||| S:1477 E:1485 ||| VBG
to  ||| S:1485 E:1497 ||| TO
B.  ||| S:1497 E:1500 ||| NNP
mori  ||| S:1500 E:1505 ||| FW
BBMV  ||| S:1505 E:1510 ||| FW
[  ||| S:1510 E:1512 ||| -LRB-
5  ||| S:1512 E:1514 ||| LS
]  ||| S:1514 E:1516 ||| -RRB-
.  ||| S:1516 E:1526 ||| .
Recently ||| S:1526 E:1534 ||| RB
,  ||| S:1534 E:1536 ||| ,
research  ||| S:1536 E:1545 ||| NN
on  ||| S:1545 E:1557 ||| IN
B.  ||| S:1557 E:1560 ||| NNP
mori  ||| S:1560 E:1565 ||| NN
has  ||| S:1565 E:1569 ||| VBZ
focused  ||| S:1569 E:1577 ||| VBN
on  ||| S:1577 E:1580 ||| IN
purifying  ||| S:1580 E:1590 ||| NN
and  ||| S:1590 E:1602 ||| CC
cloning  ||| S:1602 E:1610 ||| VBG
the  ||| S:1610 E:1614 ||| DT
midgut  ||| S:1614 E:1621 ||| JJ
epithelial  ||| S:1621 E:1632 ||| NNS
receptors  ||| S:1632 E:1642 ||| VBP
targeted  ||| S:1642 E:1651 ||| VBN
by  ||| S:1651 E:1654 ||| IN
Cry1Aa  ||| S:1654 E:1669 ||| CD
toxin ||| S:1669 E:1674 ||| NN
.  ||| S:1674 E:1676 ||| .
The  ||| S:1676 E:1680 ||| DT
first  ||| S:1680 E:1686 ||| JJ
toxin-binding  ||| S:1686 E:1700 ||| JJ
receptor  ||| S:1700 E:1709 ||| NN
purified  ||| S:1709 E:1718 ||| NN
from  ||| S:1718 E:1732 ||| IN
B.  ||| S:1732 E:1735 ||| NNP
mori  ||| S:1735 E:1740 ||| NN
was  ||| S:1740 E:1744 ||| VBD
a  ||| S:1744 E:1746 ||| DT
120-kDa  ||| S:1746 E:1754 ||| FW
aminopeptidase  ||| S:1754 E:1777 ||| FW
N  ||| S:1777 E:1779 ||| NNP
( ||| S:1779 E:1780 ||| -LRB-
APN ||| S:1780 E:1783 ||| NNP
) ||| S:1783 E:1784 ||| -RRB-
,  ||| S:1784 E:1786 ||| ,
which  ||| S:1786 E:1792 ||| WDT
appears  ||| S:1792 E:1800 ||| VBZ
around  ||| S:1800 E:1807 ||| RB
110-kDa  ||| S:1807 E:1815 ||| CD
on  ||| S:1815 E:1818 ||| IN
SDS-PAGE  ||| S:1818 E:1827 ||| JJ
gels  ||| S:1827 E:1832 ||| NN
when  ||| S:1832 E:1845 ||| WRB
preparative  ||| S:1845 E:1857 ||| JJ
conditions  ||| S:1857 E:1868 ||| NNS
are  ||| S:1868 E:1872 ||| VBP
used  ||| S:1872 E:1877 ||| VBN
that  ||| S:1877 E:1882 ||| IN
cleave  ||| S:1882 E:1889 ||| VBG
its  ||| S:1889 E:1901 ||| PRP$
glycosyl-phosphatidylinositol  ||| S:1901 E:1931 ||| JJ
( ||| S:1931 E:1932 ||| -LRB-
GPI ||| S:1932 E:1935 ||| NNP
)  ||| S:1935 E:1937 ||| -RRB-
anchor ||| S:1937 E:1943 ||| NN
.  ||| S:1943 E:1945 ||| .
This  ||| S:1945 E:1950 ||| DT
receptor  ||| S:1950 E:1967 ||| NN
was  ||| S:1967 E:1971 ||| VBD
shown  ||| S:1971 E:1977 ||| VBN
to  ||| S:1977 E:1980 ||| TO
bind  ||| S:1980 E:1985 ||| CD
Cry1Aa  ||| S:1985 E:1992 ||| CD
with  ||| S:1992 E:1997 ||| IN
a  ||| S:1997 E:1999 ||| DT
7.6  ||| S:1999 E:2003 ||| CD
nM  ||| S:2003 E:2006 ||| JJ
affinity ||| S:2006 E:2014 ||| NN
,  ||| S:2014 E:2016 ||| ,
as  ||| S:2016 E:2027 ||| RB
determined  ||| S:2027 E:2038 ||| VBN
by  ||| S:2038 E:2041 ||| IN
Scatchard  ||| S:2041 E:2051 ||| NNP
analysis  ||| S:2051 E:2060 ||| NN
with  ||| S:2060 E:2065 ||| IN
ELISA  ||| S:2065 E:2071 ||| NNP
binding  ||| S:2071 E:2079 ||| FW
assays  ||| S:2079 E:2094 ||| FW
[  ||| S:2094 E:2096 ||| -LRB-
6  ||| S:2096 E:2098 ||| CD
]  ||| S:2098 E:2100 ||| -RRB-
.  ||| S:2100 E:2102 ||| .
The  ||| S:2102 E:2106 ||| DT
APN  ||| S:2106 E:2110 ||| NNP
was  ||| S:2110 E:2114 ||| VBD
cloned  ||| S:2114 E:2121 ||| VBN
and  ||| S:2121 E:2125 ||| CC
expressed  ||| S:2125 E:2135 ||| VBN
in  ||| S:2135 E:2147 ||| IN
E.  ||| S:2147 E:2150 ||| NNP
coli  ||| S:2150 E:2155 ||| NNS
and  ||| S:2155 E:2159 ||| CC
demonstrated  ||| S:2159 E:2172 ||| VBN
to  ||| S:2172 E:2175 ||| TO
bind  ||| S:2175 E:2188 ||| CD
Cry1Aa  ||| S:2188 E:2195 ||| CD
toxin  ||| S:2195 E:2201 ||| NN
on  ||| S:2201 E:2204 ||| IN
ligand  ||| S:2204 E:2211 ||| JJ
blots  ||| S:2211 E:2217 ||| NNS
[  ||| S:2217 E:2219 ||| -LRB-
7  ||| S:2219 E:2221 ||| CD
]  ||| S:2221 E:2223 ||| -RRB-
.  ||| S:2223 E:2225 ||| .
These  ||| S:2225 E:2231 ||| DT
results  ||| S:2231 E:2239 ||| NNS
indicate  ||| S:2239 E:2256 ||| VBP
the  ||| S:2256 E:2260 ||| DT
Cry1Aa-APN  ||| S:2260 E:2271 ||| CD
interaction  ||| S:2271 E:2283 ||| NNS
was  ||| S:2283 E:2287 ||| VBD
specific  ||| S:2287 E:2296 ||| JJ
and  ||| S:2296 E:2300 ||| CC
that  ||| S:2300 E:2305 ||| IN
APN  ||| S:2305 E:2317 ||| NNP
glycosylation  ||| S:2317 E:2331 ||| NN
was  ||| S:2331 E:2335 ||| VBD
not  ||| S:2335 E:2339 ||| RB
required  ||| S:2339 E:2348 ||| VBN
for  ||| S:2348 E:2352 ||| IN
Cry1Aa  ||| S:2352 E:2359 ||| CD
binding ||| S:2359 E:2366 ||| NNS
.  ||| S:2366 E:2368 ||| .
This  ||| S:2368 E:2373 ||| DT
is  ||| S:2373 E:2384 ||| VBZ
not  ||| S:2384 E:2388 ||| RB
altogether  ||| S:2388 E:2399 ||| RB
surprising  ||| S:2399 E:2410 ||| JJ
because  ||| S:2410 E:2418 ||| IN
Cry1Aa  ||| S:2418 E:2425 ||| CD
binding  ||| S:2425 E:2433 ||| NN
to  ||| S:2433 E:2445 ||| TO
Manduca  ||| S:2445 E:2453 ||| NNP
sexta  ||| S:2453 E:2459 ||| VBD
APN  ||| S:2459 E:2463 ||| NNP
has  ||| S:2463 E:2467 ||| VBZ
not  ||| S:2467 E:2471 ||| RB
been  ||| S:2471 E:2476 ||| VBN
found  ||| S:2476 E:2490 ||| VBN
to  ||| S:2490 E:2493 ||| TO
be  ||| S:2493 E:2496 ||| VB
modulated  ||| S:2496 E:2506 ||| VBN
by  ||| S:2506 E:2509 ||| IN
sugar  ||| S:2509 E:2515 ||| NN
binding  ||| S:2515 E:2523 ||| NNS
[  ||| S:2523 E:2525 ||| -LRB-
8  ||| S:2525 E:2527 ||| CD
]  ||| S:2527 E:2529 ||| -RRB-
and  ||| S:2529 E:2533 ||| CC
the  ||| S:2533 E:2546 ||| DT
B.  ||| S:2546 E:2549 ||| NNP
mori  ||| S:2549 E:2554 ||| FW
APN  ||| S:2554 E:2558 ||| FW
sequence  ||| S:2558 E:2567 ||| FW
is  ||| S:2567 E:2570 ||| VBZ
73.7 ||| S:2570 E:2574 ||| CD
%  ||| S:2574 E:2584 ||| NN
identical  ||| S:2584 E:2594 ||| NN
to  ||| S:2594 E:2606 ||| TO
M.  ||| S:2606 E:2609 ||| NNP
sexta  ||| S:2609 E:2615 ||| VBD
APN-1 ||| S:2615 E:2620 ||| CD
.  ||| S:2620 E:2622 ||| .
Sequence  ||| S:2622 E:2631 ||| JJ
alignments  ||| S:2631 E:2650 ||| NN
with  ||| S:2650 E:2664 ||| IN
Plutella  ||| S:2664 E:2673 ||| NNP
xylostella  ||| S:2673 E:2684 ||| FW
APN  ||| S:2684 E:2688 ||| FW
receptor  ||| S:2688 E:2705 ||| FW
indicate  ||| S:2705 E:2714 ||| VBP
that  ||| S:2714 E:2719 ||| IN
a  ||| S:2719 E:2721 ||| DT
highly  ||| S:2721 E:2728 ||| RB
conserved  ||| S:2728 E:2738 ||| JJ
region  ||| S:2738 E:2745 ||| NN
of  ||| S:2745 E:2748 ||| IN
APN  ||| S:2748 E:2752 ||| NNP
likely  ||| S:2752 E:2767 ||| JJ
functions  ||| S:2767 E:2777 ||| NNS
as  ||| S:2777 E:2780 ||| IN
the  ||| S:2780 E:2784 ||| DT
toxin  ||| S:2784 E:2790 ||| NN
binding  ||| S:2790 E:2798 ||| JJ
site  ||| S:2798 E:2803 ||| NN
[  ||| S:2803 E:2805 ||| -LRB-
9  ||| S:2805 E:2807 ||| CD
]  ||| S:2807 E:2809 ||| -RRB-
.  ||| S:2809 E:2811 ||| .
By  ||| S:2811 E:2814 ||| IN
testing  ||| S:2814 E:2822 ||| NN
for  ||| S:2822 E:2834 ||| IN
toxin  ||| S:2834 E:2840 ||| NN
binding  ||| S:2840 E:2848 ||| VBG
to  ||| S:2848 E:2851 ||| TO
lysylendopeptidase-digested  ||| S:2851 E:2888 ||| NNP
B.  ||| S:2888 E:2891 ||| NNP
mori  ||| S:2891 E:2896 ||| FW
APN  ||| S:2896 E:2900 ||| FW
fragments ||| S:2900 E:2909 ||| FW
,  ||| S:2909 E:2911 ||| ,
the  ||| S:2911 E:2915 ||| DT
toxin  ||| S:2915 E:2929 ||| NN
binding  ||| S:2929 E:2937 ||| JJ
site  ||| S:2937 E:2942 ||| NN
was  ||| S:2942 E:2946 ||| VBD
suggested  ||| S:2946 E:2956 ||| VBN
to  ||| S:2956 E:2959 ||| TO
be  ||| S:2959 E:2962 ||| VB
between  ||| S:2962 E:2970 ||| IN
Ile135  ||| S:2970 E:2977 ||| NNP
and  ||| S:2977 E:2981 ||| CC
Pro198 ||| S:2981 E:2987 ||| NNP
.  ||| S:2987 E:2997 ||| .
A  ||| S:2997 E:2999 ||| DT
later  ||| S:2999 E:3005 ||| JJ
study  ||| S:3005 E:3011 ||| NN
by  ||| S:3011 E:3014 ||| IN
these  ||| S:3014 E:3020 ||| DT
authors  ||| S:3020 E:3028 ||| NNS
identified  ||| S:3028 E:3039 ||| VBD
120-kDa  ||| S:3039 E:3047 ||| CD
and  ||| S:3047 E:3059 ||| CC
115-kDa  ||| S:3059 E:3067 ||| CD
APNs  ||| S:3067 E:3072 ||| JJ
coeluting  ||| S:3072 E:3082 ||| NN
from  ||| S:3082 E:3087 ||| IN
an  ||| S:3087 E:3090 ||| DT
anion-exchange  ||| S:3090 E:3105 ||| JJ
column  ||| S:3105 E:3112 ||| NN
that  ||| S:3112 E:3125 ||| WDT
together  ||| S:3125 E:3134 ||| RB
yielded  ||| S:3134 E:3142 ||| VBD
a  ||| S:3142 E:3144 ||| DT
Cry1Aa  ||| S:3144 E:3151 ||| JJ
affinity  ||| S:3151 E:3160 ||| NN
of  ||| S:3160 E:3163 ||| IN
53  ||| S:3163 E:3166 ||| CD
nM  ||| S:3166 E:3169 ||| NNS
[  ||| S:3169 E:3171 ||| -LRB-
10  ||| S:3171 E:3174 ||| CD
]  ||| S:3174 E:3176 ||| -RRB-
.  ||| S:3176 E:3178 ||| .
These  ||| S:3178 E:3192 ||| DT
APNs  ||| S:3192 E:3197 ||| JJ
eluted  ||| S:3197 E:3204 ||| NNS
just  ||| S:3204 E:3209 ||| RB
prior  ||| S:3209 E:3215 ||| RB
to  ||| S:3215 E:3218 ||| TO
a  ||| S:3218 E:3220 ||| DT
120  ||| S:3220 E:3224 ||| CD
kDa  ||| S:3224 E:3228 ||| JJ
APN  ||| S:3228 E:3232 ||| NN
with  ||| S:3232 E:3237 ||| IN
7.6  ||| S:3237 E:3241 ||| CD
nM  ||| S:3241 E:3252 ||| JJ
affinity ||| S:3252 E:3260 ||| NN
.  ||| S:3260 E:3262 ||| .
It  ||| S:3262 E:3265 ||| PRP
is  ||| S:3265 E:3268 ||| VBZ
unclear  ||| S:3268 E:3276 ||| JJ
whether  ||| S:3276 E:3284 ||| IN
the  ||| S:3284 E:3288 ||| DT
120-  ||| S:3288 E:3293 ||| NNP
and  ||| S:3293 E:3297 ||| CC
115-kDa  ||| S:3297 E:3313 ||| CD
proteins  ||| S:3313 E:3322 ||| NNS
represent  ||| S:3322 E:3332 ||| VBP
uncleaved  ||| S:3332 E:3342 ||| VBN
and  ||| S:3342 E:3346 ||| CC
cleaved  ||| S:3346 E:3354 ||| JJ
GPI-anchor  ||| S:3354 E:3373 ||| JJ
isozymes ||| S:3373 E:3381 ||| NN
.  ||| S:3381 E:3383 ||| .
Interestingly ||| S:3383 E:3396 ||| RB
,  ||| S:3396 E:3398 ||| ,
this  ||| S:3398 E:3403 ||| DT
study  ||| S:3403 E:3409 ||| NN
also  ||| S:3409 E:3414 ||| RB
showed  ||| S:3414 E:3421 ||| VBD
that  ||| S:3421 E:3426 ||| IN
Cry1Ac  ||| S:3426 E:3441 ||| CD
toxin  ||| S:3441 E:3447 ||| NN
binds  ||| S:3447 E:3453 ||| NN
to  ||| S:3453 E:3456 ||| TO
the  ||| S:3456 E:3460 ||| DT
120 ||| S:3460 E:3463 ||| CD
/ ||| S:3463 E:3464 ||| CD
115  ||| S:3464 E:3468 ||| CD
kDa  ||| S:3468 E:3472 ||| JJ
APN  ||| S:3472 E:3476 ||| NNP
fraction  ||| S:3476 E:3485 ||| NN
with  ||| S:3485 E:3490 ||| IN
equal  ||| S:3490 E:3504 ||| JJ
affinity  ||| S:3504 E:3513 ||| NN
as  ||| S:3513 E:3516 ||| IN
Cry1Aa ||| S:3516 E:3522 ||| NNP
,  ||| S:3522 E:3524 ||| ,
and  ||| S:3524 E:3528 ||| CC
only  ||| S:3528 E:3533 ||| RB
4-fold  ||| S:3533 E:3540 ||| RB
reduced  ||| S:3540 E:3548 ||| VBN
affinity  ||| S:3548 E:3557 ||| VBN
to  ||| S:3557 E:3560 ||| TO
the  ||| S:3560 E:3572 ||| DT
isolated  ||| S:3572 E:3581 ||| JJ
120-kDa  ||| S:3581 E:3589 ||| NNP
APN ||| S:3589 E:3592 ||| NNP
.  ||| S:3592 E:3594 ||| .
Nonetheless ||| S:3594 E:3605 ||| RB
,  ||| S:3605 E:3607 ||| ,
Cry1Aa  ||| S:3607 E:3614 ||| NNP
is  ||| S:3614 E:3617 ||| VBZ
210  ||| S:3617 E:3621 ||| CD
times  ||| S:3621 E:3627 ||| NNS
more  ||| S:3627 E:3640 ||| RBR
toxic  ||| S:3640 E:3646 ||| JJ
than  ||| S:3646 E:3651 ||| IN
Cry1Ac  ||| S:3651 E:3658 ||| CD
to  ||| S:3658 E:3670 ||| TO
B.  ||| S:3670 E:3673 ||| NNP
mori  ||| S:3673 E:3678 ||| NNS
[  ||| S:3678 E:3680 ||| -LRB-
4  ||| S:3680 E:3682 ||| LS
]  ||| S:3682 E:3684 ||| -RRB-
.  ||| S:3684 E:3686 ||| .
As  ||| S:3686 E:3689 ||| IN
a  ||| S:3689 E:3691 ||| DT
whole ||| S:3691 E:3696 ||| NN
,  ||| S:3696 E:3707 ||| ,
B.  ||| S:3707 E:3710 ||| NNP
mori  ||| S:3710 E:3715 ||| VBD
APN  ||| S:3715 E:3719 ||| NNP
research  ||| S:3719 E:3728 ||| NN
indicates  ||| S:3728 E:3738 ||| VBZ
the  ||| S:3738 E:3750 ||| DT
presence  ||| S:3750 E:3759 ||| NN
of  ||| S:3759 E:3762 ||| IN
at  ||| S:3762 E:3765 ||| IN
least  ||| S:3765 E:3771 ||| JJS
three  ||| S:3771 E:3777 ||| CD
genetic  ||| S:3777 E:3785 ||| JJ
isoforms  ||| S:3785 E:3794 ||| NNS
[  ||| S:3794 E:3796 ||| -LRB-
7  ||| S:3796 E:3798 ||| CD
11  ||| S:3798 E:3801 ||| CD
12  ||| S:3801 E:3804 ||| CD
]  ||| S:3804 E:3806 ||| -RRB-
,  ||| S:3806 E:3816 ||| ,
with  ||| S:3816 E:3821 ||| IN
toxin  ||| S:3821 E:3827 ||| NN
affinities  ||| S:3827 E:3838 ||| NNS
ranging  ||| S:3838 E:3846 ||| VBG
from  ||| S:3846 E:3851 ||| IN
nanomolar  ||| S:3851 E:3861 ||| VBG
to  ||| S:3861 E:3864 ||| TO
none  ||| S:3864 E:3869 ||| NN
at  ||| S:3869 E:3880 ||| IN
all ||| S:3880 E:3883 ||| DT
.  ||| S:3883 E:3893 ||| .
In  ||| S:3893 E:3896 ||| IN
addition  ||| S:3896 E:3905 ||| NN
to  ||| S:3905 E:3908 ||| TO
APN ||| S:3908 E:3911 ||| NNP
,  ||| S:3911 E:3913 ||| ,
a  ||| S:3913 E:3915 ||| DT
completely  ||| S:3915 E:3926 ||| RB
different  ||| S:3926 E:3936 ||| JJ
toxin  ||| S:3936 E:3950 ||| NN
receptor  ||| S:3950 E:3959 ||| NN
class  ||| S:3959 E:3965 ||| NN
has  ||| S:3965 E:3969 ||| VBZ
been  ||| S:3969 E:3974 ||| VBN
affinity  ||| S:3974 E:3983 ||| JJ
precipitated  ||| S:3983 E:3996 ||| NN
by  ||| S:3996 E:3999 ||| IN
toxin  ||| S:3999 E:4005 ||| NN
from  ||| S:4005 E:4018 ||| IN
solubilized  ||| S:4018 E:4039 ||| JJ
B.  ||| S:4039 E:4042 ||| NNP
mori  ||| S:4042 E:4047 ||| VBD
midgut  ||| S:4047 E:4054 ||| JJ
proteins ||| S:4054 E:4062 ||| NNS
.  ||| S:4062 E:4064 ||| .
In  ||| S:4064 E:4067 ||| IN
this  ||| S:4067 E:4080 ||| DT
manner ||| S:4080 E:4086 ||| NN
,  ||| S:4086 E:4088 ||| ,
Nagamatsu  ||| S:4088 E:4107 ||| FW
et  ||| S:4107 E:4110 ||| FW
al.  ||| S:4110 E:4114 ||| FW
[  ||| S:4114 E:4116 ||| -LRB-
13  ||| S:4116 E:4119 ||| CD
]  ||| S:4119 E:4121 ||| -RRB-
purified  ||| S:4121 E:4130 ||| FW
a  ||| S:4130 E:4132 ||| FW
175-kDa  ||| S:4132 E:4148 ||| FW
glycoprotein  ||| S:4148 E:4161 ||| FW
( ||| S:4161 E:4162 ||| -LRB-
BtR175 ||| S:4162 E:4168 ||| NNP
)  ||| S:4168 E:4170 ||| -RRB-
that  ||| S:4170 E:4175 ||| IN
bound  ||| S:4175 E:4181 ||| CD
Cry1Aa  ||| S:4181 E:4188 ||| CD
toxin ||| S:4188 E:4193 ||| NN
.  ||| S:4193 E:4203 ||| .
Interestingly ||| S:4203 E:4216 ||| RB
,  ||| S:4216 E:4218 ||| ,
these  ||| S:4218 E:4224 ||| DT
authors  ||| S:4224 E:4232 ||| NNS
did  ||| S:4232 E:4236 ||| VBD
not  ||| S:4236 E:4240 ||| RB
observe  ||| S:4240 E:4248 ||| VBP
binding  ||| S:4248 E:4256 ||| VBG
of  ||| S:4256 E:4267 ||| IN
Cry1Aa  ||| S:4267 E:4274 ||| CD
to  ||| S:4274 E:4277 ||| TO
APN-sized  ||| S:4277 E:4287 ||| JJ
bands  ||| S:4287 E:4293 ||| NNS
in  ||| S:4293 E:4296 ||| IN
ligand  ||| S:4296 E:4303 ||| JJ
blot  ||| S:4303 E:4308 ||| JJ
studies  ||| S:4308 E:4316 ||| NNS
with  ||| S:4316 E:4321 ||| IN
BBMV ||| S:4321 E:4325 ||| NNP
.  ||| S:4325 E:4335 ||| .
Antibodies  ||| S:4335 E:4346 ||| NNS
produced  ||| S:4346 E:4355 ||| VBN
to  ||| S:4355 E:4358 ||| TO
BtR175  ||| S:4358 E:4365 ||| CD
blocked  ||| S:4365 E:4373 ||| JJ
toxin  ||| S:4373 E:4379 ||| NN
binding  ||| S:4379 E:4387 ||| VBG
to  ||| S:4387 E:4390 ||| TO
the  ||| S:4390 E:4402 ||| DT
receptor  ||| S:4402 E:4411 ||| NN
in  ||| S:4411 E:4414 ||| IN
BBMV ||| S:4414 E:4418 ||| NNP
.  ||| S:4418 E:4420 ||| .
The  ||| S:4420 E:4424 ||| DT
antibody  ||| S:4424 E:4433 ||| NN
serum  ||| S:4433 E:4439 ||| VBZ
also  ||| S:4439 E:4444 ||| RB
reduced  ||| S:4444 E:4452 ||| VBD
Cry1Aa  ||| S:4452 E:4467 ||| CD
activity  ||| S:4467 E:4476 ||| NN
against  ||| S:4476 E:4493 ||| IN
B.  ||| S:4493 E:4496 ||| NNP
mori  ||| S:4496 E:4501 ||| NN
when  ||| S:4501 E:4506 ||| WRB
it  ||| S:4506 E:4509 ||| PRP
was  ||| S:4509 E:4513 ||| VBD
fed  ||| S:4513 E:4517 ||| VBN
to  ||| S:4517 E:4520 ||| TO
larvae  ||| S:4520 E:4535 ||| VB
prior  ||| S:4535 E:4541 ||| RB
to  ||| S:4541 E:4544 ||| TO
toxin  ||| S:4544 E:4550 ||| NN
addition  ||| S:4550 E:4559 ||| NN
to  ||| S:4559 E:4562 ||| TO
the  ||| S:4562 E:4566 ||| DT
diet  ||| S:4566 E:4571 ||| NN
[  ||| S:4571 E:4573 ||| -LRB-
14  ||| S:4573 E:4576 ||| CD
]  ||| S:4576 E:4578 ||| -RRB-
.  ||| S:4578 E:4580 ||| .
The  ||| S:4580 E:4584 ||| DT
same  ||| S:4584 E:4589 ||| JJ
group  ||| S:4589 E:4603 ||| NN
cloned  ||| S:4603 E:4610 ||| NNS
and  ||| S:4610 E:4614 ||| CC
introduced  ||| S:4614 E:4625 ||| VBD
the  ||| S:4625 E:4629 ||| DT
BtR175  ||| S:4629 E:4636 ||| JJ
gene  ||| S:4636 E:4641 ||| NN
with  ||| S:4641 E:4646 ||| IN
a  ||| S:4646 E:4648 ||| DT
baculovirus  ||| S:4648 E:4668 ||| JJ
vector  ||| S:4668 E:4675 ||| NN
into  ||| S:4675 E:4689 ||| IN
Spodptera  ||| S:4689 E:4699 ||| NNP
frugiperda  ||| S:4699 E:4710 ||| VBD
Sf9  ||| S:4710 E:4714 ||| CD
cells ||| S:4714 E:4719 ||| NNS
.  ||| S:4719 E:4729 ||| .
Addition  ||| S:4729 E:4738 ||| NN
of  ||| S:4738 E:4741 ||| IN
Cry1Aa  ||| S:4741 E:4748 ||| NNP
caused  ||| S:4748 E:4755 ||| VBD
swelling  ||| S:4755 E:4764 ||| VBG
and  ||| S:4764 E:4768 ||| CC
lysis  ||| S:4768 E:4774 ||| NN
of  ||| S:4774 E:4777 ||| IN
only  ||| S:4777 E:4782 ||| RB
the  ||| S:4782 E:4794 ||| DT
Sf9  ||| S:4794 E:4798 ||| CD
cells  ||| S:4798 E:4804 ||| NNS
expressing  ||| S:4804 E:4815 ||| VBG
BtR175 ||| S:4815 E:4821 ||| CD
.  ||| S:4821 E:4823 ||| .
Based  ||| S:4823 E:4829 ||| VBN
on  ||| S:4829 E:4832 ||| IN
sequence  ||| S:4832 E:4841 ||| JJ
analysis ||| S:4841 E:4849 ||| NN
,  ||| S:4849 E:4859 ||| ,
the  ||| S:4859 E:4863 ||| DT
receptor  ||| S:4863 E:4872 ||| NN
was  ||| S:4872 E:4876 ||| VBD
characterized  ||| S:4876 E:4890 ||| VBN
as  ||| S:4890 E:4893 ||| IN
a  ||| S:4893 E:4895 ||| DT
cadherin-like  ||| S:4895 E:4917 ||| JJ
glycoprotein  ||| S:4917 E:4930 ||| NNS
containing  ||| S:4930 E:4941 ||| VBG
nine  ||| S:4941 E:4946 ||| CD
cadherin  ||| S:4946 E:4955 ||| CD
repeats ||| S:4955 E:4962 ||| NNS
,  ||| S:4962 E:4964 ||| ,
a  ||| S:4964 E:4966 ||| DT
membrane  ||| S:4966 E:4983 ||| JJ
proximal  ||| S:4983 E:4992 ||| JJ
region ||| S:4992 E:4998 ||| NN
,  ||| S:4998 E:5000 ||| ,
one  ||| S:5000 E:5004 ||| CD
transmembrane  ||| S:5004 E:5018 ||| JJ
region ||| S:5018 E:5024 ||| NN
,  ||| S:5024 E:5026 ||| ,
and  ||| S:5026 E:5030 ||| CC
a  ||| S:5030 E:5032 ||| DT
small  ||| S:5032 E:5046 ||| JJ
cytoplasmic  ||| S:5046 E:5058 ||| JJ
domain  ||| S:5058 E:5065 ||| NN
[  ||| S:5065 E:5067 ||| -LRB-
15  ||| S:5067 E:5070 ||| CD
]  ||| S:5070 E:5072 ||| -RRB-
.  ||| S:5072 E:5074 ||| .
Ihara  ||| S:5074 E:5089 ||| FW
et  ||| S:5089 E:5092 ||| FW
al.  ||| S:5092 E:5096 ||| FW
[  ||| S:5096 E:5098 ||| -LRB-
16  ||| S:5098 E:5101 ||| CD
]  ||| S:5101 E:5103 ||| -RRB-
also  ||| S:5103 E:5108 ||| RB
purified  ||| S:5108 E:5117 ||| JJ
and  ||| S:5117 E:5129 ||| CC
partially  ||| S:5129 E:5139 ||| RB
sequenced  ||| S:5139 E:5149 ||| VB
what  ||| S:5149 E:5154 ||| WP
was  ||| S:5154 E:5158 ||| VBD
presumed  ||| S:5158 E:5167 ||| VBN
to  ||| S:5167 E:5170 ||| TO
be  ||| S:5170 E:5173 ||| VB
the  ||| S:5173 E:5177 ||| DT
same  ||| S:5177 E:5190 ||| JJ
cadherin-like  ||| S:5190 E:5204 ||| JJ
receptor ||| S:5204 E:5212 ||| NN
.  ||| S:5212 E:5214 ||| .
Binding  ||| S:5214 E:5222 ||| JJ
studies  ||| S:5222 E:5230 ||| NNS
indicated  ||| S:5230 E:5240 ||| VBD
that  ||| S:5240 E:5245 ||| IN
the  ||| S:5245 E:5257 ||| DT
affinity  ||| S:5257 E:5266 ||| NN
of  ||| S:5266 E:5269 ||| IN
the  ||| S:5269 E:5273 ||| DT
cadherin  ||| S:5273 E:5282 ||| NN
for  ||| S:5282 E:5286 ||| IN
Cry1Aa  ||| S:5286 E:5293 ||| NNP
is  ||| S:5293 E:5296 ||| VBZ
equivalent  ||| S:5296 E:5307 ||| JJ
to  ||| S:5307 E:5310 ||| TO
that  ||| S:5310 E:5323 ||| DT
of  ||| S:5323 E:5326 ||| IN
the  ||| S:5326 E:5330 ||| DT
brush  ||| S:5330 E:5336 ||| JJ
border  ||| S:5336 E:5343 ||| NN
membrane  ||| S:5343 E:5352 ||| NN
vesicles  ||| S:5352 E:5361 ||| NN
from  ||| S:5361 E:5375 ||| IN
B.  ||| S:5375 E:5378 ||| NNP
mori  ||| S:5378 E:5383 ||| NNS
[  ||| S:5383 E:5385 ||| -LRB-
16  ||| S:5385 E:5388 ||| CD
]  ||| S:5388 E:5390 ||| -RRB-
,  ||| S:5390 E:5392 ||| ,
an  ||| S:5392 E:5395 ||| DT
affinity  ||| S:5395 E:5404 ||| NN
that  ||| S:5404 E:5409 ||| WDT
is  ||| S:5409 E:5420 ||| VBZ
substantially  ||| S:5420 E:5434 ||| RB
lower  ||| S:5434 E:5440 ||| JJR
than  ||| S:5440 E:5445 ||| IN
the  ||| S:5445 E:5449 ||| DT
APN  ||| S:5449 E:5453 ||| NNP
affinities  ||| S:5453 E:5464 ||| NNS
reported ||| S:5464 E:5472 ||| VBD
.  ||| S:5472 E:5482 ||| .
Recently ||| S:5482 E:5490 ||| RB
,  ||| S:5490 E:5492 ||| ,
cDNA  ||| S:5492 E:5497 ||| JJ
variants  ||| S:5497 E:5506 ||| NN
of  ||| S:5506 E:5509 ||| IN
BtR175  ||| S:5509 E:5516 ||| NNP
have  ||| S:5516 E:5521 ||| VBP
been  ||| S:5521 E:5526 ||| VBN
discovered ||| S:5526 E:5536 ||| VBN
,  ||| S:5536 E:5546 ||| ,
showing  ||| S:5546 E:5554 ||| VBG
at  ||| S:5554 E:5557 ||| IN
least  ||| S:5557 E:5563 ||| JJS
three  ||| S:5563 E:5569 ||| CD
alleles  ||| S:5569 E:5577 ||| NN
of  ||| S:5577 E:5580 ||| IN
the  ||| S:5580 E:5584 ||| DT
cadherin-like  ||| S:5584 E:5606 ||| JJ
receptor  ||| S:5606 E:5615 ||| NNS
are  ||| S:5615 E:5619 ||| VBP
found  ||| S:5619 E:5625 ||| VBN
in  ||| S:5625 E:5637 ||| IN
B.  ||| S:5637 E:5640 ||| NNP
mori  ||| S:5640 E:5645 ||| NNS
[  ||| S:5645 E:5647 ||| -LRB-
17  ||| S:5647 E:5650 ||| CD
]  ||| S:5650 E:5652 ||| -RRB-
.  ||| S:5652 E:5654 ||| .
It  ||| S:5654 E:5657 ||| PRP
is  ||| S:5657 E:5660 ||| VBZ
likely  ||| S:5660 E:5667 ||| RB
that  ||| S:5667 E:5680 ||| IN
glycosylation  ||| S:5680 E:5694 ||| NN
plays  ||| S:5694 E:5700 ||| VBZ
a  ||| S:5700 E:5702 ||| DT
major  ||| S:5702 E:5708 ||| JJ
role  ||| S:5708 E:5713 ||| NN
in  ||| S:5713 E:5716 ||| IN
cadherin-like  ||| S:5716 E:5730 ||| JJ
receptor  ||| S:5730 E:5747 ||| NN
isoforms  ||| S:5747 E:5756 ||| NN
as  ||| S:5756 E:5759 ||| IN
well ||| S:5759 E:5763 ||| RB
,  ||| S:5763 E:5765 ||| ,
as  ||| S:5765 E:5768 ||| IN
glycosylation  ||| S:5768 E:5782 ||| NN
has  ||| S:5782 E:5786 ||| VBZ
been  ||| S:5786 E:5791 ||| VBN
observed  ||| S:5791 E:5808 ||| VBN
previously  ||| S:5808 E:5819 ||| RB
for  ||| S:5819 E:5823 ||| IN
the  ||| S:5823 E:5836 ||| DT
M.  ||| S:5836 E:5839 ||| NNP
sexta  ||| S:5839 E:5845 ||| VBD
cadherin-like  ||| S:5845 E:5859 ||| JJ
receptor  ||| S:5859 E:5868 ||| NN
BT-R  ||| S:5868 E:5882 ||| JJ
1  ||| S:5882 E:5884 ||| CD
[  ||| S:5884 E:5886 ||| -LRB-
18  ||| S:5886 E:5889 ||| CD
]  ||| S:5889 E:5891 ||| -RRB-
.  ||| S:5891 E:5901 ||| .
Progress  ||| S:5901 E:5910 ||| NN
in  ||| S:5910 E:5913 ||| IN
research  ||| S:5913 E:5922 ||| NN
on  ||| S:5922 E:5925 ||| IN
silkworm  ||| S:5925 E:5934 ||| JJ
receptors  ||| S:5934 E:5944 ||| NNS
for  ||| S:5944 E:5948 ||| IN
Bt  ||| S:5948 E:5951 ||| NNP
toxins  ||| S:5951 E:5966 ||| NN
has  ||| S:5966 E:5970 ||| VBZ
provided  ||| S:5970 E:5979 ||| VBN
a  ||| S:5979 E:5981 ||| DT
means  ||| S:5981 E:5987 ||| NNS
for  ||| S:5987 E:5991 ||| IN
assaying  ||| S:5991 E:6000 ||| JJ
mutant  ||| S:6000 E:6007 ||| JJ
toxins  ||| S:6007 E:6014 ||| NN
with  ||| S:6014 E:6027 ||| IN
potentially  ||| S:6027 E:6039 ||| RB
altered  ||| S:6039 E:6047 ||| VBN
binding  ||| S:6047 E:6055 ||| JJ
and  ||| S:6055 E:6059 ||| CC
activity ||| S:6059 E:6067 ||| NN
.  ||| S:6067 E:6069 ||| .
In  ||| S:6069 E:6072 ||| IN
this  ||| S:6072 E:6077 ||| DT
study ||| S:6077 E:6082 ||| NN
,  ||| S:6082 E:6084 ||| ,
we  ||| S:6084 E:6095 ||| PRP
tested  ||| S:6095 E:6102 ||| VBD
the  ||| S:6102 E:6106 ||| DT
hypothesis  ||| S:6106 E:6117 ||| NN
that  ||| S:6117 E:6122 ||| IN
Cry1Aa  ||| S:6122 E:6129 ||| CD
binds  ||| S:6129 E:6135 ||| NN
to  ||| S:6135 E:6138 ||| TO
both  ||| S:6138 E:6143 ||| PDT
the  ||| S:6143 E:6147 ||| DT
120-kDa  ||| S:6147 E:6172 ||| NNP
B.  ||| S:6172 E:6175 ||| NNP
mori  ||| S:6175 E:6180 ||| VBD
APN  ||| S:6180 E:6184 ||| NNP
and  ||| S:6184 E:6188 ||| CC
the  ||| S:6188 E:6192 ||| DT
175-kDa  ||| S:6192 E:6209 ||| NNP
B.  ||| S:6209 E:6212 ||| NNP
mori  ||| S:6212 E:6217 ||| VBD
cadherin-like  ||| S:6217 E:6231 ||| JJ
protein ||| S:6231 E:6238 ||| NN
.  ||| S:6238 E:6240 ||| .
Based  ||| S:6240 E:6254 ||| VBN
on  ||| S:6254 E:6257 ||| IN
the  ||| S:6257 E:6261 ||| DT
previous  ||| S:6261 E:6270 ||| JJ
work  ||| S:6270 E:6275 ||| NN
of  ||| S:6275 E:6278 ||| IN
Ge ||| S:6278 E:6280 ||| NNP
,  ||| S:6280 E:6282 ||| ,
et  ||| S:6282 E:6285 ||| FW
al.  ||| S:6285 E:6289 ||| FW
[  ||| S:6289 E:6291 ||| -LRB-
3  ||| S:6291 E:6293 ||| LS
]  ||| S:6293 E:6295 ||| -RRB-
and  ||| S:6295 E:6299 ||| CC
Lee ||| S:6299 E:6302 ||| NNP
,  ||| S:6302 E:6304 ||| ,
et  ||| S:6304 E:6307 ||| FW
al.  ||| S:6307 E:6311 ||| FW
[  ||| S:6311 E:6321 ||| -LRB-
4  ||| S:6321 E:6323 ||| LS
]  ||| S:6323 E:6325 ||| -RRB-
,  ||| S:6325 E:6327 ||| ,
we  ||| S:6327 E:6330 ||| PRP
also  ||| S:6330 E:6335 ||| RB
postulated  ||| S:6335 E:6346 ||| VBN
that  ||| S:6346 E:6351 ||| IN
domain  ||| S:6351 E:6358 ||| JJ
II  ||| S:6358 E:6361 ||| NNP
of  ||| S:6361 E:6364 ||| IN
Cry1Aa  ||| S:6364 E:6371 ||| NNP
is  ||| S:6371 E:6374 ||| VBZ
the  ||| S:6374 E:6386 ||| DT
significant  ||| S:6386 E:6398 ||| JJ
binding  ||| S:6398 E:6406 ||| JJ
domain ||| S:6406 E:6412 ||| NN
.  ||| S:6412 E:6414 ||| .
These  ||| S:6414 E:6420 ||| DT
hypotheses  ||| S:6420 E:6431 ||| NN
were  ||| S:6431 E:6436 ||| VBD
tested  ||| S:6436 E:6451 ||| VBN
for  ||| S:6451 E:6455 ||| IN
the  ||| S:6455 E:6459 ||| DT
first  ||| S:6459 E:6465 ||| JJ
time  ||| S:6465 E:6470 ||| NN
in  ||| S:6470 E:6473 ||| IN
studies  ||| S:6473 E:6481 ||| NNS
with  ||| S:6481 E:6486 ||| IN
purified ||| S:6486 E:6494 ||| NN
,  ||| S:6494 E:6496 ||| ,
native  ||| S:6496 E:6512 ||| JJ
B.  ||| S:6512 E:6515 ||| NNP
mori  ||| S:6515 E:6520 ||| FW
receptors  ||| S:6520 E:6530 ||| FW
( ||| S:6530 E:6531 ||| -LRB-
rather  ||| S:6531 E:6538 ||| RB
than  ||| S:6538 E:6543 ||| IN
BBMV ||| S:6543 E:6547 ||| NNP
)  ||| S:6547 E:6557 ||| -RRB-
under  ||| S:6557 E:6563 ||| IN
real-time ||| S:6563 E:6572 ||| JJ
,  ||| S:6572 E:6574 ||| ,
non-labeled  ||| S:6574 E:6586 ||| JJ
toxin  ||| S:6586 E:6592 ||| NN
binding  ||| S:6592 E:6600 ||| JJ
conditions ||| S:6600 E:6610 ||| NNS
.  ||| S:6610 E:6634 ||| .
Results  ||| S:6634 E:6661 ||| FW
Bombyx  ||| S:6661 E:6668 ||| FW
mori  ||| S:6668 E:6673 ||| FW
aminopeptidase  ||| S:6673 E:6688 ||| FW
N  ||| S:6688 E:6690 ||| NNP
and  ||| S:6690 E:6694 ||| CC
cadherin-like  ||| S:6694 E:6718 ||| JJ
receptor  ||| S:6718 E:6727 ||| NN
purification  ||| S:6727 E:6750 ||| NN
To  ||| S:6750 E:6753 ||| TO
investigate  ||| S:6753 E:6765 ||| VB
the  ||| S:6765 E:6769 ||| DT
specificity  ||| S:6769 E:6781 ||| NN
of  ||| S:6781 E:6784 ||| IN
Cry  ||| S:6784 E:6788 ||| NNP
toxins  ||| S:6788 E:6795 ||| NN
for  ||| S:6795 E:6810 ||| IN
B.  ||| S:6810 E:6813 ||| NNP
mori  ||| S:6813 E:6818 ||| NN
receptors ||| S:6818 E:6827 ||| NNS
,  ||| S:6827 E:6829 ||| ,
the  ||| S:6829 E:6833 ||| DT
two  ||| S:6833 E:6837 ||| CD
known  ||| S:6837 E:6854 ||| VBN
B.  ||| S:6854 E:6857 ||| NNP
mori  ||| S:6857 E:6862 ||| VBD
midgut  ||| S:6862 E:6869 ||| JJ
receptors  ||| S:6869 E:6879 ||| NNS
were  ||| S:6879 E:6894 ||| VBD
purified  ||| S:6894 E:6903 ||| VBN
from  ||| S:6903 E:6919 ||| IN
B.  ||| S:6919 E:6922 ||| NNP
mori  ||| S:6922 E:6927 ||| VBD
BBMV ||| S:6927 E:6931 ||| NNP
.  ||| S:6931 E:6933 ||| .
Solubilized  ||| S:6933 E:6956 ||| NNP
B.  ||| S:6956 E:6959 ||| NNP
mori  ||| S:6959 E:6964 ||| VBD
BBMV  ||| S:6964 E:6969 ||| NNP
proteins  ||| S:6969 E:6978 ||| NNS
were  ||| S:6978 E:6993 ||| VBD
separated  ||| S:6993 E:7003 ||| VBN
by  ||| S:7003 E:7006 ||| IN
Q  ||| S:7006 E:7008 ||| NNP
Sepharose  ||| S:7008 E:7018 ||| NNP
anion-exchange  ||| S:7018 E:7033 ||| JJ
chromatography  ||| S:7033 E:7058 ||| NN
and  ||| S:7058 E:7062 ||| CC
all  ||| S:7062 E:7066 ||| DT
eluted  ||| S:7066 E:7073 ||| JJ
fractions  ||| S:7073 E:7083 ||| NNS
were  ||| S:7083 E:7088 ||| VBD
tested  ||| S:7088 E:7095 ||| VBN
for  ||| S:7095 E:7099 ||| IN
APN  ||| S:7099 E:7103 ||| NNP
enzymatic  ||| S:7103 E:7123 ||| JJ
activity ||| S:7123 E:7131 ||| NN
.  ||| S:7131 E:7133 ||| .
Additionally ||| S:7133 E:7145 ||| RB
,  ||| S:7145 E:7147 ||| ,
Cry1Aa  ||| S:7147 E:7154 ||| CD
toxin  ||| S:7154 E:7160 ||| NN
binding  ||| S:7160 E:7168 ||| JJ
capability  ||| S:7168 E:7189 ||| NN
was  ||| S:7189 E:7193 ||| VBD
assayed  ||| S:7193 E:7201 ||| VBN
by  ||| S:7201 E:7204 ||| IN
"slot  ||| S:7204 E:7210 ||| CD
blotting ||| S:7210 E:7218 ||| NN
"  ||| S:7218 E:7220 ||| ''
all  ||| S:7220 E:7224 ||| DT
fractions  ||| S:7224 E:7234 ||| NN
and  ||| S:7234 E:7238 ||| CC
probing  ||| S:7238 E:7256 ||| VBG
with  ||| S:7256 E:7261 ||| IN
biotin-Cry1Aa ||| S:7261 E:7274 ||| CD
.  ||| S:7274 E:7276 ||| .
The  ||| S:7276 E:7280 ||| DT
chromatogram  ||| S:7280 E:7293 ||| NN
in  ||| S:7293 E:7296 ||| IN
Fig.  ||| S:7296 E:7301 ||| CD
1displays  ||| S:7301 E:7321 ||| CD
the  ||| S:7321 E:7325 ||| DT
separation  ||| S:7325 E:7336 ||| NN
of  ||| S:7336 E:7339 ||| IN
cadherin  ||| S:7339 E:7348 ||| NN
and  ||| S:7348 E:7352 ||| CC
APN  ||| S:7352 E:7356 ||| NNP
from  ||| S:7356 E:7361 ||| IN
BBMV  ||| S:7361 E:7366 ||| NNP
proteins ||| S:7366 E:7374 ||| NNS
.  ||| S:7374 E:7386 ||| .
APN  ||| S:7386 E:7390 ||| NNP
isozymes  ||| S:7390 E:7399 ||| NN
of  ||| S:7399 E:7402 ||| IN
100-  ||| S:7402 E:7407 ||| NNP
and  ||| S:7407 E:7411 ||| CC
110-kDa  ||| S:7411 E:7419 ||| NNP
were  ||| S:7419 E:7424 ||| VBD
detected  ||| S:7424 E:7433 ||| VBN
that  ||| S:7433 E:7438 ||| WDT
did  ||| S:7438 E:7452 ||| VBD
not  ||| S:7452 E:7456 ||| RB
show  ||| S:7456 E:7461 ||| VB
Cry1Aa-binding  ||| S:7461 E:7476 ||| CD
in  ||| S:7476 E:7479 ||| IN
slot  ||| S:7479 E:7484 ||| FW
blot  ||| S:7484 E:7489 ||| FW
assays  ||| S:7489 E:7496 ||| FW
( ||| S:7496 E:7497 ||| -LRB-
Fig.  ||| S:7497 E:7502 ||| CD
1 ||| S:7502 E:7503 ||| CD
;  ||| S:7503 E:7515 ||| :
fractions  ||| S:7515 E:7525 ||| CD
24-25  ||| S:7525 E:7531 ||| CD
and  ||| S:7531 E:7535 ||| CC
30-31 ||| S:7535 E:7540 ||| CD
) ||| S:7540 E:7541 ||| -RRB-
.  ||| S:7541 E:7543 ||| .
Such  ||| S:7543 E:7548 ||| JJ
isozymes  ||| S:7548 E:7557 ||| NNS
have  ||| S:7557 E:7562 ||| VBP
been  ||| S:7562 E:7577 ||| VBN
reported  ||| S:7577 E:7586 ||| VBN
previously  ||| S:7586 E:7597 ||| RB
[  ||| S:7597 E:7599 ||| -LRB-
11  ||| S:7599 E:7602 ||| CD
12  ||| S:7602 E:7605 ||| CD
]  ||| S:7605 E:7607 ||| -RRB-
.  ||| S:7607 E:7609 ||| .
In  ||| S:7609 E:7612 ||| IN
addition ||| S:7612 E:7620 ||| NN
,  ||| S:7620 E:7622 ||| ,
a  ||| S:7622 E:7624 ||| DT
115-kDa  ||| S:7624 E:7642 ||| NNP
APN  ||| S:7642 E:7646 ||| NNP
was  ||| S:7646 E:7650 ||| VBD
detected  ||| S:7650 E:7659 ||| VBN
with  ||| S:7659 E:7664 ||| IN
Cry1Aa-binding  ||| S:7664 E:7679 ||| CD
capability  ||| S:7679 E:7690 ||| NN
( ||| S:7690 E:7691 ||| -LRB-
Fig.  ||| S:7691 E:7696 ||| CD
1 ||| S:7696 E:7697 ||| CD
;  ||| S:7697 E:7709 ||| :
fractions  ||| S:7709 E:7719 ||| CD
33-36 ||| S:7719 E:7724 ||| CD
) ||| S:7724 E:7725 ||| -RRB-
.  ||| S:7725 E:7727 ||| .
As  ||| S:7727 E:7730 ||| RB
expected ||| S:7730 E:7738 ||| VBN
,  ||| S:7738 E:7740 ||| ,
fractions  ||| S:7740 E:7750 ||| NNS
were  ||| S:7750 E:7755 ||| VBD
also  ||| S:7755 E:7770 ||| RB
observed  ||| S:7770 E:7779 ||| VBN
that  ||| S:7779 E:7784 ||| IN
exhibited  ||| S:7784 E:7794 ||| VBG
no  ||| S:7794 E:7797 ||| DT
APN  ||| S:7797 E:7801 ||| NNP
enzymatic  ||| S:7801 E:7811 ||| JJ
activity  ||| S:7811 E:7820 ||| NN
but  ||| S:7820 E:7834 ||| CC
bound  ||| S:7834 E:7840 ||| JJ
Cry1Aa  ||| S:7840 E:7847 ||| NN
on  ||| S:7847 E:7850 ||| IN
slot  ||| S:7850 E:7855 ||| NN
blots  ||| S:7855 E:7861 ||| NNS
( ||| S:7861 E:7862 ||| -LRB-
Fig.  ||| S:7862 E:7867 ||| CD
1 ||| S:7867 E:7868 ||| CD
;  ||| S:7868 E:7870 ||| :
fractions  ||| S:7870 E:7880 ||| CD
26-27 ||| S:7880 E:7885 ||| CD
) ||| S:7885 E:7886 ||| -RRB-
.  ||| S:7886 E:7898 ||| .
Initially  ||| S:7898 E:7908 ||| RB
these  ||| S:7908 E:7914 ||| DT
fractions  ||| S:7914 E:7924 ||| NN
were  ||| S:7924 E:7929 ||| VBD
predicted  ||| S:7929 E:7939 ||| VBN
to  ||| S:7939 E:7942 ||| TO
contain  ||| S:7942 E:7950 ||| VB
the  ||| S:7950 E:7964 ||| DT
cadherin-like  ||| S:7964 E:7978 ||| JJ
Cry1Aa-binding  ||| S:7978 E:7993 ||| CD
protein  ||| S:7993 E:8001 ||| NN
[  ||| S:8001 E:8003 ||| -LRB-
13  ||| S:8003 E:8006 ||| CD
14  ||| S:8006 E:8009 ||| CD
16  ||| S:8009 E:8012 ||| CD
]  ||| S:8012 E:8014 ||| -RRB-
.  ||| S:8014 E:8016 ||| .
The  ||| S:8016 E:8030 ||| DT
candidate  ||| S:8030 E:8040 ||| NN
receptor  ||| S:8040 E:8049 ||| NN
fractions  ||| S:8049 E:8059 ||| NNS
for  ||| S:8059 E:8063 ||| IN
APN  ||| S:8063 E:8067 ||| NNP
and  ||| S:8067 E:8071 ||| CC
cadherin  ||| S:8071 E:8080 ||| NNS
were  ||| S:8080 E:8095 ||| VBD
separately  ||| S:8095 E:8106 ||| RB
loaded  ||| S:8106 E:8113 ||| VBN
on  ||| S:8113 E:8116 ||| IN
a  ||| S:8116 E:8118 ||| DT
size-exclusion  ||| S:8118 E:8133 ||| JJ
column  ||| S:8133 E:8140 ||| NN
for  ||| S:8140 E:8144 ||| IN
further  ||| S:8144 E:8162 ||| JJ
purification  ||| S:8162 E:8175 ||| NNS
( ||| S:8175 E:8176 ||| -LRB-
Fig.  ||| S:8176 E:8181 ||| CD
2Aand  ||| S:8181 E:8187 ||| CD
2B ||| S:8187 E:8189 ||| CD
) ||| S:8189 E:8190 ||| -RRB-
.  ||| S:8190 E:8192 ||| .
A  ||| S:8192 E:8194 ||| DT
protein  ||| S:8194 E:8202 ||| NN
with  ||| S:8202 E:8207 ||| IN
APN  ||| S:8207 E:8221 ||| NNP
enzymatic  ||| S:8221 E:8231 ||| JJ
activity  ||| S:8231 E:8240 ||| NN
eluted  ||| S:8240 E:8247 ||| VBD
75  ||| S:8247 E:8250 ||| CD
minutes  ||| S:8250 E:8258 ||| NNS
after  ||| S:8258 E:8264 ||| IN
injection  ||| S:8264 E:8284 ||| NN
( ||| S:8284 E:8285 ||| -LRB-
Fig.  ||| S:8285 E:8290 ||| NNP
2A ||| S:8290 E:8292 ||| NNP
;  ||| S:8292 E:8294 ||| :
fractions  ||| S:8294 E:8304 ||| CD
15-16 ||| S:8304 E:8309 ||| CD
) ||| S:8309 E:8310 ||| -RRB-
,  ||| S:8310 E:8312 ||| ,
approximately  ||| S:8312 E:8326 ||| RB
4  ||| S:8326 E:8328 ||| CD
minutes  ||| S:8328 E:8336 ||| NNS
after  ||| S:8336 E:8352 ||| IN
the  ||| S:8352 E:8356 ||| DT
120-kDa  ||| S:8356 E:8375 ||| NNP
L.  ||| S:8375 E:8378 ||| NNP
dispar  ||| S:8378 E:8385 ||| FW
APN  ||| S:8385 E:8389 ||| FW
elutes  ||| S:8389 E:8396 ||| FW
on  ||| S:8396 E:8399 ||| IN
the  ||| S:8399 E:8403 ||| DT
same  ||| S:8403 E:8418 ||| JJ
column  ||| S:8418 E:8425 ||| NN
[  ||| S:8425 E:8427 ||| -LRB-
19  ||| S:8427 E:8430 ||| CD
]  ||| S:8430 E:8432 ||| -RRB-
.  ||| S:8432 E:8434 ||| .
The  ||| S:8434 E:8438 ||| DT
candidate  ||| S:8438 E:8448 ||| NN
cadherin-like  ||| S:8448 E:8462 ||| JJ
receptor  ||| S:8462 E:8481 ||| NN
fraction  ||| S:8481 E:8490 ||| NN
eluted  ||| S:8490 E:8497 ||| NN
in  ||| S:8497 E:8500 ||| IN
fractions  ||| S:8500 E:8510 ||| CD
9-11  ||| S:8510 E:8515 ||| CD
at  ||| S:8515 E:8518 ||| IN
around  ||| S:8518 E:8525 ||| IN
180  ||| S:8525 E:8529 ||| CD
kDa  ||| S:8529 E:8533 ||| NNS
( ||| S:8533 E:8534 ||| -LRB-
Fig.  ||| S:8534 E:8549 ||| NNP
2B ||| S:8549 E:8551 ||| NNP
) ||| S:8551 E:8552 ||| -RRB-
.  ||| S:8552 E:8582 ||| .
Analysis  ||| S:8582 E:8591 ||| NN
of  ||| S:8591 E:8594 ||| IN
receptor  ||| S:8594 E:8603 ||| NN
purity  ||| S:8603 E:8620 ||| VBD
The  ||| S:8620 E:8624 ||| DT
pooled  ||| S:8624 E:8631 ||| NN
and  ||| S:8631 E:8635 ||| CC
concentrated  ||| S:8635 E:8648 ||| JJ
candidate  ||| S:8648 E:8658 ||| NN
receptor  ||| S:8658 E:8677 ||| NN
fractions  ||| S:8677 E:8687 ||| NNS
were  ||| S:8687 E:8692 ||| VBD
examined  ||| S:8692 E:8701 ||| VBN
by  ||| S:8701 E:8704 ||| IN
SDS-PAGE  ||| S:8704 E:8713 ||| JJ
before  ||| S:8713 E:8720 ||| IN
and  ||| S:8720 E:8724 ||| CC
after  ||| S:8724 E:8740 ||| IN
size-exclusion  ||| S:8740 E:8755 ||| JJ
purification  ||| S:8755 E:8768 ||| NN
to  ||| S:8768 E:8771 ||| TO
assess  ||| S:8771 E:8778 ||| VB
purity  ||| S:8778 E:8785 ||| NNS
( ||| S:8785 E:8786 ||| -LRB-
Fig.  ||| S:8786 E:8791 ||| CD
3 ||| S:8791 E:8792 ||| CD
) ||| S:8792 E:8793 ||| -RRB-
.  ||| S:8793 E:8805 ||| .
The  ||| S:8805 E:8809 ||| DT
putative  ||| S:8809 E:8818 ||| JJ
cadherin-like  ||| S:8818 E:8832 ||| JJ
receptor  ||| S:8832 E:8841 ||| NN
material  ||| S:8841 E:8850 ||| NN
appears  ||| S:8850 E:8858 ||| VBZ
at  ||| S:8858 E:8861 ||| IN
a  ||| S:8861 E:8873 ||| DT
molecular  ||| S:8873 E:8883 ||| JJ
size  ||| S:8883 E:8888 ||| NN
around  ||| S:8888 E:8895 ||| IN
180  ||| S:8895 E:8899 ||| CD
kDa ||| S:8899 E:8902 ||| NN
,  ||| S:8902 E:8904 ||| ,
both  ||| S:8904 E:8909 ||| DT
before  ||| S:8909 E:8916 ||| RB
and  ||| S:8916 E:8920 ||| CC
after  ||| S:8920 E:8936 ||| IN
secondary  ||| S:8936 E:8946 ||| JJ
purification  ||| S:8946 E:8959 ||| NNS
( ||| S:8959 E:8960 ||| -LRB-
Lanes  ||| S:8960 E:8966 ||| NNP
2  ||| S:8966 E:8968 ||| CD
and  ||| S:8968 E:8972 ||| CC
1 ||| S:8972 E:8973 ||| CD
,  ||| S:8973 E:8975 ||| ,
respectively ||| S:8975 E:8987 ||| RB
) ||| S:8987 E:8988 ||| -RRB-
.  ||| S:8988 E:9000 ||| .
Several  ||| S:9000 E:9008 ||| JJ
BBMV  ||| S:9008 E:9013 ||| NN
proteins  ||| S:9013 E:9022 ||| NNS
appear  ||| S:9022 E:9029 ||| VBP
present  ||| S:9029 E:9037 ||| JJ
in  ||| S:9037 E:9040 ||| IN
the  ||| S:9040 E:9054 ||| DT
APN-containing  ||| S:9054 E:9069 ||| JJ
fraction  ||| S:9069 E:9078 ||| NN
prior  ||| S:9078 E:9084 ||| RB
to  ||| S:9084 E:9087 ||| TO
size-exclusion  ||| S:9087 E:9112 ||| JJ
purification  ||| S:9112 E:9125 ||| NNS
( ||| S:9125 E:9126 ||| -LRB-
Fig.  ||| S:9126 E:9131 ||| CD
3 ||| S:9131 E:9132 ||| CD
;  ||| S:9132 E:9134 ||| :
Lane  ||| S:9134 E:9139 ||| NNP
4 ||| S:9139 E:9140 ||| CD
) ||| S:9140 E:9141 ||| -RRB-
.  ||| S:9141 E:9143 ||| .
The  ||| S:9143 E:9147 ||| DT
molecular  ||| S:9147 E:9157 ||| JJ
weight  ||| S:9157 E:9164 ||| NN
of  ||| S:9164 E:9177 ||| IN
the  ||| S:9177 E:9181 ||| DT
final ||| S:9181 E:9186 ||| JJ
,  ||| S:9186 E:9188 ||| ,
purified  ||| S:9188 E:9197 ||| VBG
APN  ||| S:9197 E:9201 ||| NNP
was  ||| S:9201 E:9205 ||| VBD
estimated  ||| S:9205 E:9215 ||| VBN
to  ||| S:9215 E:9218 ||| TO
be  ||| S:9218 E:9221 ||| VB
115-120  ||| S:9221 E:9229 ||| NNP
kDa  ||| S:9229 E:9243 ||| NNP
( ||| S:9243 E:9244 ||| -LRB-
Fig.  ||| S:9244 E:9249 ||| CD
3 ||| S:9249 E:9250 ||| CD
;  ||| S:9250 E:9252 ||| :
Lane  ||| S:9252 E:9257 ||| NNP
3 ||| S:9257 E:9258 ||| CD
) ||| S:9258 E:9259 ||| -RRB-
.  ||| S:9259 E:9261 ||| .
It  ||| S:9261 E:9264 ||| PRP
is  ||| S:9264 E:9267 ||| VBZ
not  ||| S:9267 E:9271 ||| RB
known  ||| S:9271 E:9277 ||| VBN
whether  ||| S:9277 E:9285 ||| IN
the  ||| S:9285 E:9289 ||| DT
GPI  ||| S:9289 E:9293 ||| NNP
anchor  ||| S:9293 E:9310 ||| NN
is  ||| S:9310 E:9313 ||| VBZ
still  ||| S:9313 E:9319 ||| RB
intact  ||| S:9319 E:9326 ||| JJ
on  ||| S:9326 E:9329 ||| IN
the  ||| S:9329 E:9333 ||| DT
APN  ||| S:9333 E:9337 ||| NNP
receptor ||| S:9337 E:9345 ||| NN
;  ||| S:9345 E:9347 ||| :
however ||| S:9347 E:9354 ||| RB
,  ||| S:9354 E:9356 ||| ,
in  ||| S:9356 E:9359 ||| IN
the  ||| S:9359 E:9373 ||| DT
current  ||| S:9373 E:9381 ||| JJ
study ||| S:9381 E:9386 ||| NN
,  ||| S:9386 E:9388 ||| ,
phosphatidylinositol-specific  ||| S:9388 E:9428 ||| JJ
phospholipase  ||| S:9428 E:9442 ||| JJ
C  ||| S:9442 E:9444 ||| NNP
( ||| S:9444 E:9445 ||| -LRB-
PIPLC ||| S:9445 E:9450 ||| NNP
)  ||| S:9450 E:9452 ||| -RRB-
was  ||| S:9452 E:9456 ||| VBD
not  ||| S:9456 E:9460 ||| RB
used  ||| S:9460 E:9465 ||| VBN
during  ||| S:9465 E:9472 ||| IN
BBMV  ||| S:9472 E:9487 ||| NNP
preparation ||| S:9487 E:9498 ||| NN
.  ||| S:9498 E:9500 ||| .
It  ||| S:9500 E:9503 ||| PRP
was  ||| S:9503 E:9507 ||| VBD
shown  ||| S:9507 E:9513 ||| VBN
previously  ||| S:9513 E:9524 ||| RB
that  ||| S:9524 E:9529 ||| IN
APN  ||| S:9529 E:9533 ||| NNP
may  ||| S:9533 E:9537 ||| MD
be  ||| S:9537 E:9550 ||| VB
purified  ||| S:9550 E:9559 ||| VBN
with  ||| S:9559 E:9564 ||| IN
intact  ||| S:9564 E:9571 ||| JJ
GPI-anchors  ||| S:9571 E:9583 ||| NN
if  ||| S:9583 E:9586 ||| IN
PIPLC  ||| S:9586 E:9592 ||| NNP
is  ||| S:9592 E:9595 ||| VBZ
omitted  ||| S:9595 E:9603 ||| VBN
from  ||| S:9603 E:9618 ||| IN
the  ||| S:9618 E:9622 ||| DT
preparation  ||| S:9622 E:9634 ||| NN
buffer  ||| S:9634 E:9641 ||| NN
[  ||| S:9641 E:9643 ||| -LRB-
6  ||| S:9643 E:9645 ||| CD
]  ||| S:9645 E:9647 ||| -RRB-
.  ||| S:9647 E:9649 ||| .
It  ||| S:9649 E:9652 ||| PRP
is  ||| S:9652 E:9655 ||| VBZ
likely  ||| S:9655 E:9662 ||| RB
that  ||| S:9662 E:9667 ||| IN
our  ||| S:9667 E:9671 ||| PRP$
APN  ||| S:9671 E:9685 ||| NNP
has  ||| S:9685 E:9689 ||| VBZ
similarly  ||| S:9689 E:9699 ||| RB
retained  ||| S:9699 E:9708 ||| VBD
the  ||| S:9708 E:9712 ||| DT
GPI  ||| S:9712 E:9716 ||| NNP
anchor ||| S:9716 E:9722 ||| NN
.  ||| S:9722 E:9734 ||| .
In  ||| S:9734 E:9737 ||| IN
view  ||| S:9737 E:9742 ||| NN
of  ||| S:9742 E:9745 ||| IN
the  ||| S:9745 E:9749 ||| DT
fact  ||| S:9749 E:9754 ||| NN
that  ||| S:9754 E:9770 ||| IN
B.  ||| S:9770 E:9773 ||| NNP
mori  ||| S:9773 E:9778 ||| FW
BtR175  ||| S:9778 E:9785 ||| FW
possesses  ||| S:9785 E:9795 ||| FW
sequence  ||| S:9795 E:9814 ||| FW
similarity  ||| S:9814 E:9825 ||| FW
to  ||| S:9825 E:9839 ||| TO
M.  ||| S:9839 E:9842 ||| NNP
sexta  ||| S:9842 E:9848 ||| VBD
BT-R  ||| S:9848 E:9864 ||| JJ
1  ||| S:9864 E:9866 ||| CD
,  ||| S:9866 E:9868 ||| ,
the  ||| S:9868 E:9872 ||| DT
candidate  ||| S:9872 E:9882 ||| NN
fraction  ||| S:9882 E:9891 ||| NN
was  ||| S:9891 E:9895 ||| VBD
probed  ||| S:9895 E:9912 ||| VBN
on  ||| S:9912 E:9915 ||| IN
a  ||| S:9915 E:9917 ||| DT
slot  ||| S:9917 E:9922 ||| NN
blot  ||| S:9922 E:9927 ||| NN
with  ||| S:9927 E:9932 ||| IN
anti-BT-R  ||| S:9932 E:9953 ||| JJ
1  ||| S:9953 E:9955 ||| CD
polyclonal  ||| S:9955 E:9966 ||| CD
antiserum ||| S:9966 E:9975 ||| NNS
.  ||| S:9975 E:9977 ||| .
A  ||| S:9977 E:9979 ||| DT
weak  ||| S:9979 E:9984 ||| JJ
to  ||| S:9984 E:9997 ||| TO
moderate  ||| S:9997 E:10006 ||| VB
cross-reactivity  ||| S:10006 E:10023 ||| JJ
with  ||| S:10023 E:10028 ||| IN
anti-BT-R  ||| S:10028 E:10049 ||| JJ
1  ||| S:10049 E:10051 ||| CD
was  ||| S:10051 E:10055 ||| VBD
observed  ||| S:10055 E:10064 ||| VBN
for  ||| S:10064 E:10079 ||| IN
B.  ||| S:10079 E:10082 ||| NNP
mori  ||| S:10082 E:10087 ||| VBD
BBMV  ||| S:10087 E:10092 ||| NNP
as  ||| S:10092 E:10095 ||| IN
well  ||| S:10095 E:10100 ||| RB
as  ||| S:10100 E:10103 ||| IN
the  ||| S:10103 E:10117 ||| DT
putative  ||| S:10117 E:10126 ||| JJ
cadherin-like  ||| S:10126 E:10140 ||| JJ
receptor  ||| S:10140 E:10149 ||| NN
fraction ||| S:10149 E:10157 ||| NN
,  ||| S:10157 E:10159 ||| ,
providing  ||| S:10159 E:10179 ||| VBG
strong  ||| S:10179 E:10186 ||| JJ
evidence  ||| S:10186 E:10195 ||| NN
that  ||| S:10195 E:10200 ||| IN
the  ||| S:10200 E:10204 ||| DT
material  ||| S:10204 E:10213 ||| NN
is  ||| S:10213 E:10216 ||| VBZ
a  ||| S:10216 E:10218 ||| DT
cadherin-like  ||| S:10218 E:10242 ||| JJ
protein  ||| S:10242 E:10250 ||| NN
( ||| S:10250 E:10251 ||| -LRB-
Fig.  ||| S:10251 E:10256 ||| CD
4 ||| S:10256 E:10257 ||| CD
) ||| S:10257 E:10258 ||| -RRB-
.  ||| S:10258 E:10260 ||| .
Anti-Bt-R  ||| S:10260 E:10281 ||| JJ
1  ||| S:10281 E:10283 ||| CD
antibody  ||| S:10283 E:10292 ||| NN
recognition  ||| S:10292 E:10304 ||| NN
was  ||| S:10304 E:10308 ||| VBD
not  ||| S:10308 E:10322 ||| RB
observed  ||| S:10322 E:10331 ||| VBN
for  ||| S:10331 E:10335 ||| IN
fractions  ||| S:10335 E:10345 ||| JJ
eluting  ||| S:10345 E:10353 ||| NN
before  ||| S:10353 E:10360 ||| IN
and  ||| S:10360 E:10364 ||| CC
after  ||| S:10364 E:10370 ||| IN
the  ||| S:10370 E:10384 ||| DT
cadherin  ||| S:10384 E:10393 ||| JJ
material ||| S:10393 E:10401 ||| NN
,  ||| S:10401 E:10403 ||| ,
nor  ||| S:10403 E:10407 ||| CC
for  ||| S:10407 E:10411 ||| IN
the  ||| S:10411 E:10415 ||| DT
purified  ||| S:10415 E:10424 ||| JJ
APN  ||| S:10424 E:10428 ||| NNP
( ||| S:10428 E:10429 ||| -LRB-
Fig.  ||| S:10429 E:10434 ||| CD
4 ||| S:10434 E:10435 ||| CD
) ||| S:10435 E:10436 ||| -RRB-
.  ||| S:10436 E:10448 ||| .
Similar  ||| S:10448 E:10456 ||| JJ
antibody  ||| S:10456 E:10465 ||| NN
assays  ||| S:10465 E:10472 ||| NNS
were  ||| S:10472 E:10477 ||| VBD
not  ||| S:10477 E:10481 ||| RB
performed  ||| S:10481 E:10491 ||| VBN
to  ||| S:10491 E:10504 ||| TO
substantiate  ||| S:10504 E:10517 ||| VB
the  ||| S:10517 E:10521 ||| DT
identity  ||| S:10521 E:10530 ||| NN
of  ||| S:10530 E:10533 ||| IN
the  ||| S:10533 E:10537 ||| DT
purified  ||| S:10537 E:10546 ||| JJ
APN  ||| S:10546 E:10550 ||| NN
because  ||| S:10550 E:10558 ||| IN
it  ||| S:10558 E:10571 ||| PRP
clearly  ||| S:10571 E:10579 ||| RB
displayed  ||| S:10579 E:10589 ||| VBN
strong ||| S:10589 E:10595 ||| JJ
,  ||| S:10595 E:10597 ||| ,
characteristic  ||| S:10597 E:10612 ||| JJ
APN  ||| S:10612 E:10616 ||| NNP
enzyme  ||| S:10616 E:10633 ||| JJ
activity ||| S:10633 E:10641 ||| NN
.  ||| S:10641 E:10653 ||| .
The  ||| S:10653 E:10657 ||| DT
purity  ||| S:10657 E:10664 ||| NN
of  ||| S:10664 E:10667 ||| IN
both  ||| S:10667 E:10672 ||| DT
receptors  ||| S:10672 E:10682 ||| NN
was  ||| S:10682 E:10686 ||| VBD
further  ||| S:10686 E:10694 ||| RB
examined  ||| S:10694 E:10703 ||| VBN
by  ||| S:10703 E:10706 ||| IN
a  ||| S:10706 E:10718 ||| DT
Cry1Aa  ||| S:10718 E:10725 ||| FW
toxin  ||| S:10725 E:10731 ||| FW
ligand  ||| S:10731 E:10738 ||| FW
blot  ||| S:10738 E:10743 ||| FW
( ||| S:10743 E:10744 ||| -LRB-
Fig.  ||| S:10744 E:10749 ||| CD
5 ||| S:10749 E:10750 ||| CD
) ||| S:10750 E:10751 ||| -RRB-
.  ||| S:10751 E:10753 ||| .
Both  ||| S:10753 E:10758 ||| DT
APN  ||| S:10758 E:10762 ||| NNP
and  ||| S:10762 E:10766 ||| CC
the  ||| S:10766 E:10780 ||| DT
cadherin-like  ||| S:10780 E:10794 ||| JJ
receptor  ||| S:10794 E:10803 ||| FW
fractions  ||| S:10803 E:10813 ||| FW
bound  ||| S:10813 E:10819 ||| FW
biotinylated  ||| S:10819 E:10842 ||| FW
Cry1Aa ||| S:10842 E:10848 ||| FW
.  ||| S:10848 E:10850 ||| .
No  ||| S:10850 E:10853 ||| DT
other  ||| S:10853 E:10859 ||| JJ
toxin-binding  ||| S:10859 E:10873 ||| JJ
bands  ||| S:10873 E:10879 ||| NNS
were  ||| S:10879 E:10884 ||| VBD
apparent ||| S:10884 E:10892 ||| JJ
,  ||| S:10892 E:10894 ||| ,
and  ||| S:10894 E:10908 ||| CC
neither  ||| S:10908 E:10916 ||| DT
purified  ||| S:10916 E:10925 ||| JJ
receptor  ||| S:10925 E:10934 ||| NN
sample  ||| S:10934 E:10941 ||| NN
was  ||| S:10941 E:10945 ||| VBD
visibly  ||| S:10945 E:10963 ||| RB
cross-contaminated  ||| S:10963 E:10982 ||| JJ
with  ||| S:10982 E:10987 ||| IN
the  ||| S:10987 E:10991 ||| DT
other  ||| S:10991 E:10997 ||| JJ
receptor  ||| S:10997 E:11006 ||| NN
( ||| S:11006 E:11007 ||| -LRB-
Fig.  ||| S:11007 E:11012 ||| CD
5 ||| S:11012 E:11013 ||| CD
) ||| S:11013 E:11014 ||| -RRB-
.  ||| S:11014 E:11044 ||| .
Affinity  ||| S:11044 E:11053 ||| JJ
estimation  ||| S:11053 E:11064 ||| NN
by  ||| S:11064 E:11067 ||| IN
surface  ||| S:11067 E:11075 ||| FW
plasmon  ||| S:11075 E:11093 ||| FW
resonance  ||| S:11093 E:11113 ||| FW
Cry  ||| S:11113 E:11117 ||| FW
toxin  ||| S:11117 E:11123 ||| FW
binding  ||| S:11123 E:11131 ||| FW
studies  ||| S:11131 E:11139 ||| NNS
have  ||| S:11139 E:11144 ||| VBP
been  ||| S:11144 E:11149 ||| VBN
reported  ||| S:11149 E:11168 ||| VBN
previously  ||| S:11168 E:11179 ||| RB
for  ||| S:11179 E:11194 ||| IN
B.  ||| S:11194 E:11197 ||| NNP
mori  ||| S:11197 E:11202 ||| NN
that  ||| S:11202 E:11207 ||| WDT
used  ||| S:11207 E:11212 ||| VBD
BBMV  ||| S:11212 E:11217 ||| NNP
assays  ||| S:11217 E:11224 ||| NN
or  ||| S:11224 E:11237 ||| CC
used  ||| S:11237 E:11242 ||| VBN
purified  ||| S:11242 E:11251 ||| JJ
receptors  ||| S:11251 E:11261 ||| NNS
in  ||| S:11261 E:11264 ||| IN
ELISA  ||| S:11264 E:11270 ||| NNP
assays  ||| S:11270 E:11277 ||| NN
or  ||| S:11277 E:11280 ||| CC
blots ||| S:11280 E:11285 ||| NNS
;  ||| S:11285 E:11297 ||| :
however ||| S:11297 E:11304 ||| RB
,  ||| S:11304 E:11306 ||| ,
no  ||| S:11306 E:11309 ||| DT
Cry  ||| S:11309 E:11313 ||| JJ
toxin  ||| S:11313 E:11319 ||| NN
studies  ||| S:11319 E:11327 ||| NNS
concerning  ||| S:11327 E:11349 ||| VBG
B.  ||| S:11349 E:11352 ||| NNP
mori  ||| S:11352 E:11357 ||| NNS
have  ||| S:11357 E:11362 ||| VBP
been  ||| S:11362 E:11367 ||| VBN
published  ||| S:11367 E:11387 ||| VBN
employing  ||| S:11387 E:11397 ||| VBG
SPR  ||| S:11397 E:11401 ||| NNP
analysis ||| S:11401 E:11409 ||| NN
.  ||| S:11409 E:11411 ||| .
The  ||| S:11411 E:11415 ||| DT
affinity  ||| S:11415 E:11424 ||| NN
of  ||| S:11424 E:11427 ||| IN
Cry1Aa  ||| S:11427 E:11434 ||| CD
binding  ||| S:11434 E:11442 ||| NN
to  ||| S:11442 E:11466 ||| TO
B.  ||| S:11466 E:11469 ||| NNP
mori  ||| S:11469 E:11474 ||| VBD
APN  ||| S:11474 E:11478 ||| NNP
and  ||| S:11478 E:11493 ||| CC
B.  ||| S:11493 E:11496 ||| NNP
mori  ||| S:11496 E:11501 ||| VBD
cadherin  ||| S:11501 E:11510 ||| JJ
receptors  ||| S:11510 E:11520 ||| NNS
was  ||| S:11520 E:11534 ||| VBD
evaluated  ||| S:11534 E:11544 ||| VBN
by  ||| S:11544 E:11547 ||| IN
real-time  ||| S:11547 E:11557 ||| JJ
kinetic  ||| S:11557 E:11565 ||| JJ
analysis  ||| S:11565 E:11574 ||| NN
on  ||| S:11574 E:11577 ||| IN
a  ||| S:11577 E:11579 ||| DT
BIAcore  ||| S:11579 E:11597 ||| JJ
2000 ||| S:11597 E:11601 ||| CD
.  ||| S:11601 E:11603 ||| .
Simple  ||| S:11603 E:11610 ||| JJ
bimolecular  ||| S:11610 E:11622 ||| JJ
binding  ||| S:11622 E:11630 ||| NN
of  ||| S:11630 E:11633 ||| IN
Cry1Aa  ||| S:11633 E:11640 ||| NNP
was  ||| S:11640 E:11644 ||| VBD
observed  ||| S:11644 E:11663 ||| VBN
to  ||| S:11663 E:11666 ||| TO
both  ||| S:11666 E:11682 ||| DT
B.  ||| S:11682 E:11685 ||| NNP
mori  ||| S:11685 E:11690 ||| VBD
APN  ||| S:11690 E:11694 ||| NNP
and  ||| S:11694 E:11698 ||| CC
cadherin  ||| S:11698 E:11707 ||| NNS
( ||| S:11707 E:11708 ||| -LRB-
Fig.  ||| S:11708 E:11723 ||| CD
6Aand  ||| S:11723 E:11729 ||| CD
6B ||| S:11729 E:11731 ||| CD
) ||| S:11731 E:11732 ||| -RRB-
.  ||| S:11732 E:11734 ||| .
Toxin-receptor  ||| S:11734 E:11749 ||| JJ
on-rates  ||| S:11749 E:11758 ||| NN
for  ||| S:11758 E:11762 ||| IN
association  ||| S:11762 E:11774 ||| NN
(  ||| S:11774 E:11787 ||| -LRB-
k  ||| S:11787 E:11800 ||| FW
a  ||| S:11800 E:11802 ||| FW
) ||| S:11802 E:11803 ||| -RRB-
,  ||| S:11803 E:11805 ||| ,
off-rates  ||| S:11805 E:11815 ||| JJ
for  ||| S:11815 E:11819 ||| IN
dissociation  ||| S:11819 E:11832 ||| NNS
(  ||| S:11832 E:11845 ||| -LRB-
k  ||| S:11845 E:11858 ||| UH
d  ||| S:11858 E:11860 ||| LS
) ||| S:11860 E:11861 ||| -RRB-
,  ||| S:11861 E:11863 ||| ,
and  ||| S:11863 E:11867 ||| CC
overall  ||| S:11867 E:11875 ||| JJ
binding  ||| S:11875 E:11883 ||| JJ
affinity  ||| S:11883 E:11892 ||| NNS
(  ||| S:11892 E:11905 ||| -LRB-
k  ||| S:11905 E:11918 ||| FW
d  ||| S:11918 E:11920 ||| FW
/  ||| S:11920 E:11933 ||| FW
k  ||| S:11933 E:11946 ||| FW
a  ||| S:11946 E:11948 ||| FW
,  ||| S:11948 E:11950 ||| ,
or  ||| S:11950 E:11964 ||| CC
K  ||| S:11964 E:11977 ||| NNP
D  ||| S:11977 E:11979 ||| NNP
)  ||| S:11979 E:11981 ||| -RRB-
were  ||| S:11981 E:11986 ||| VBD
calculated  ||| S:11986 E:11997 ||| VBN
for  ||| S:11997 E:12001 ||| IN
toxin  ||| S:12001 E:12007 ||| NN
binding ||| S:12007 E:12014 ||| NN
.  ||| S:12014 E:12026 ||| .
The  ||| S:12026 E:12030 ||| DT
apparent  ||| S:12030 E:12039 ||| JJ
rate  ||| S:12039 E:12044 ||| NN
constants  ||| S:12044 E:12054 ||| NN
for  ||| S:12054 E:12058 ||| IN
wild-type  ||| S:12058 E:12068 ||| NNP
Cry1Aa  ||| S:12068 E:12075 ||| NNP
and  ||| S:12075 E:12090 ||| CC
B.  ||| S:12090 E:12093 ||| NNP
mori  ||| S:12093 E:12098 ||| VBD
APN  ||| S:12098 E:12102 ||| NNP
were  ||| S:12102 E:12118 ||| VBD
k  ||| S:12118 E:12131 ||| VBN
a  ||| S:12131 E:12133 ||| DT
=  ||| S:12133 E:12135 ||| CD
2.0  ||| S:12135 E:12139 ||| CD
×  ||| S:12139 E:12141 ||| CD
10  ||| S:12141 E:12144 ||| CD
4M  ||| S:12144 E:12147 ||| CD
-1s  ||| S:12147 E:12151 ||| CD
-1 ||| S:12151 E:12153 ||| CD
( ||| S:12153 E:12154 ||| -LRB-
+ ||| S:12154 E:12155 ||| NNP
/ ||| S:12155 E:12156 ||| NNP
-  ||| S:12156 E:12158 ||| :
1.3  ||| S:12158 E:12162 ||| CD
×  ||| S:12162 E:12164 ||| CD
10  ||| S:12164 E:12177 ||| CD
2 ||| S:12177 E:12178 ||| CD
) ||| S:12178 E:12179 ||| -RRB-
,  ||| S:12179 E:12192 ||| ,
k  ||| S:12192 E:12205 ||| VBG
d  ||| S:12205 E:12207 ||| SYM
=  ||| S:12207 E:12209 ||| SYM
1.5  ||| S:12209 E:12213 ||| CD
×  ||| S:12213 E:12215 ||| CD
10  ||| S:12215 E:12218 ||| CD
-3s  ||| S:12218 E:12222 ||| CD
-1 ||| S:12222 E:12224 ||| CD
( ||| S:12224 E:12225 ||| -LRB-
+ ||| S:12225 E:12226 ||| NNP
/ ||| S:12226 E:12227 ||| NNP
-  ||| S:12227 E:12229 ||| :
1  ||| S:12229 E:12231 ||| CD
×  ||| S:12231 E:12233 ||| CD
10  ||| S:12233 E:12236 ||| CD
-5 ||| S:12236 E:12238 ||| CD
) ||| S:12238 E:12239 ||| -RRB-
,  ||| S:12239 E:12251 ||| ,
and  ||| S:12251 E:12266 ||| CC
K  ||| S:12266 E:12279 ||| NNP
D  ||| S:12279 E:12281 ||| NNP
=  ||| S:12281 E:12283 ||| SYM
75  ||| S:12283 E:12286 ||| CD
nM ||| S:12286 E:12288 ||| NN
.  ||| S:12288 E:12290 ||| .
To  ||| S:12290 E:12304 ||| TO
B.  ||| S:12304 E:12307 ||| NNP
mori  ||| S:12307 E:12312 ||| JJ
cadherin ||| S:12312 E:12320 ||| NN
,  ||| S:12320 E:12322 ||| ,
significantly  ||| S:12322 E:12346 ||| RB
tighter  ||| S:12346 E:12354 ||| JJR
affinities  ||| S:12354 E:12365 ||| NNS
were  ||| S:12365 E:12370 ||| VBD
obtained ||| S:12370 E:12378 ||| VBN
:  ||| S:12378 E:12391 ||| :
k  ||| S:12391 E:12404 ||| VBG
a  ||| S:12404 E:12406 ||| DT
=  ||| S:12406 E:12408 ||| CD
1.3  ||| S:12408 E:12412 ||| CD
×  ||| S:12412 E:12414 ||| CD
10  ||| S:12414 E:12417 ||| CD
4M  ||| S:12417 E:12420 ||| CD
-1s  ||| S:12420 E:12424 ||| CD
-1 ||| S:12424 E:12426 ||| CD
( ||| S:12426 E:12427 ||| -LRB-
+ ||| S:12427 E:12428 ||| NNP
/ ||| S:12428 E:12429 ||| NNP
-  ||| S:12429 E:12431 ||| :
6.1 ||| S:12431 E:12434 ||| CD
) ||| S:12434 E:12435 ||| -RRB-
,  ||| S:12435 E:12448 ||| ,
k  ||| S:12448 E:12461 ||| VBG
d  ||| S:12461 E:12463 ||| SYM
=  ||| S:12463 E:12465 ||| SYM
3.3  ||| S:12465 E:12469 ||| CD
×  ||| S:12469 E:12471 ||| CD
10  ||| S:12471 E:12474 ||| CD
-5s  ||| S:12474 E:12478 ||| CD
-1 ||| S:12478 E:12480 ||| CD
( ||| S:12480 E:12481 ||| -LRB-
+ ||| S:12481 E:12482 ||| NNP
/ ||| S:12482 E:12483 ||| NNP
-  ||| S:12483 E:12485 ||| :
1  ||| S:12485 E:12487 ||| CD
×  ||| S:12487 E:12489 ||| CD
10  ||| S:12489 E:12492 ||| CD
-5 ||| S:12492 E:12494 ||| CD
) ||| S:12494 E:12495 ||| -RRB-
,  ||| S:12495 E:12508 ||| ,
K  ||| S:12508 E:12521 ||| NNP
D  ||| S:12521 E:12523 ||| NNP
=  ||| S:12523 E:12525 ||| SYM
2.6  ||| S:12525 E:12529 ||| CD
nM ||| S:12529 E:12531 ||| NN
.  ||| S:12531 E:12533 ||| .
This  ||| S:12533 E:12538 ||| DT
apparent  ||| S:12538 E:12547 ||| JJ
off-rate  ||| S:12547 E:12566 ||| NN
clearly  ||| S:12566 E:12574 ||| RB
accounted  ||| S:12574 E:12584 ||| VBN
for  ||| S:12584 E:12588 ||| IN
Cry1Aa ||| S:12588 E:12594 ||| NNP
's  ||| S:12594 E:12597 ||| POS
higher  ||| S:12597 E:12604 ||| JJR
affinity  ||| S:12604 E:12613 ||| NN
for  ||| S:12613 E:12627 ||| IN
cadherin  ||| S:12627 E:12636 ||| NN
than  ||| S:12636 E:12641 ||| IN
for  ||| S:12641 E:12645 ||| IN
APN ||| S:12645 E:12648 ||| NNP
.  ||| S:12648 E:12650 ||| .
The  ||| S:12650 E:12654 ||| DT
cadherin  ||| S:12654 E:12663 ||| JJ
off-rate  ||| S:12663 E:12672 ||| NN
observed  ||| S:12672 E:12681 ||| VBD
in  ||| S:12681 E:12694 ||| IN
this  ||| S:12694 E:12699 ||| DT
study  ||| S:12699 E:12705 ||| NN
could  ||| S:12705 E:12711 ||| MD
have  ||| S:12711 E:12716 ||| VB
significant  ||| S:12716 E:12728 ||| JJ
consequences  ||| S:12728 E:12741 ||| NNS
in  ||| S:12741 E:12744 ||| IN
vivo ||| S:12744 E:12748 ||| NNS
:  ||| S:12748 E:12760 ||| :
slow  ||| S:12760 E:12765 ||| JJ
toxin  ||| S:12765 E:12771 ||| NN
dissociation  ||| S:12771 E:12784 ||| NNS
may  ||| S:12784 E:12788 ||| MD
enable  ||| S:12788 E:12795 ||| VB
protracted  ||| S:12795 E:12806 ||| JJ
lingering  ||| S:12806 E:12826 ||| NN
near  ||| S:12826 E:12831 ||| IN
the  ||| S:12831 E:12835 ||| DT
brush  ||| S:12835 E:12841 ||| JJ
border  ||| S:12841 E:12848 ||| NN
membrane  ||| S:12848 E:12857 ||| NN
surface ||| S:12857 E:12864 ||| NN
,  ||| S:12864 E:12866 ||| ,
greatly  ||| S:12866 E:12884 ||| RB
facilitating  ||| S:12884 E:12897 ||| VBG
toxic  ||| S:12897 E:12903 ||| JJ
( ||| S:12903 E:12904 ||| -LRB-
domain  ||| S:12904 E:12911 ||| NN
I ||| S:12911 E:12912 ||| PRP
)  ||| S:12912 E:12914 ||| -RRB-
insertion  ||| S:12914 E:12924 ||| NN
and  ||| S:12924 E:12928 ||| CC
subsequent  ||| S:12928 E:12949 ||| JJ
pore  ||| S:12949 E:12954 ||| JJ
formation ||| S:12954 E:12963 ||| NN
.  ||| S:12963 E:12965 ||| .
The  ||| S:12965 E:12969 ||| DT
overall  ||| S:12969 E:12977 ||| JJ
affinity  ||| S:12977 E:12986 ||| NNS
determined  ||| S:12986 E:12997 ||| VBN
in  ||| S:12997 E:13000 ||| IN
the  ||| S:13000 E:13014 ||| DT
present  ||| S:13014 E:13022 ||| JJ
study  ||| S:13022 E:13028 ||| NN
for  ||| S:13028 E:13032 ||| IN
Cry1Aa  ||| S:13032 E:13039 ||| CD
to  ||| S:13039 E:13042 ||| TO
BtR175  ||| S:13042 E:13049 ||| CD
( ||| S:13049 E:13050 ||| -LRB-
2.6  ||| S:13050 E:13054 ||| CD
nM ||| S:13054 E:13056 ||| NN
)  ||| S:13056 E:13058 ||| -RRB-
agrees  ||| S:13058 E:13065 ||| VBZ
well  ||| S:13065 E:13080 ||| RB
with  ||| S:13080 E:13085 ||| IN
the  ||| S:13085 E:13089 ||| DT
findings  ||| S:13089 E:13098 ||| NNS
of  ||| S:13098 E:13101 ||| IN
Ihara  ||| S:13101 E:13118 ||| NNP
et  ||| S:13118 E:13121 ||| FW
al.  ||| S:13121 E:13125 ||| FW
[  ||| S:13125 E:13127 ||| -LRB-
16  ||| S:13127 E:13130 ||| CD
]  ||| S:13130 E:13132 ||| -RRB-
by  ||| S:13132 E:13135 ||| IN
a  ||| S:13135 E:13137 ||| DT
different  ||| S:13137 E:13147 ||| JJ
assay  ||| S:13147 E:13163 ||| NNS
( ||| S:13163 E:13164 ||| -LRB-
0.8  ||| S:13164 E:13168 ||| NNP
nM ||| S:13168 E:13170 ||| NNP
) ||| S:13170 E:13171 ||| -RRB-
.  ||| S:13171 E:13183 ||| .
We  ||| S:13183 E:13186 ||| PRP
also  ||| S:13186 E:13191 ||| RB
explored  ||| S:13191 E:13200 ||| VB
the  ||| S:13200 E:13204 ||| DT
specificity  ||| S:13204 E:13216 ||| NN
of  ||| S:13216 E:13219 ||| IN
Cry1Aa  ||| S:13219 E:13226 ||| CD
for  ||| S:13226 E:13230 ||| IN
the  ||| S:13230 E:13244 ||| DT
native  ||| S:13244 E:13262 ||| JJ
B.  ||| S:13262 E:13265 ||| NNP
mori  ||| S:13265 E:13270 ||| NN
receptors  ||| S:13270 E:13280 ||| NNS
by  ||| S:13280 E:13283 ||| IN
comparing  ||| S:13283 E:13293 ||| VBG
the  ||| S:13293 E:13307 ||| DT
binding  ||| S:13307 E:13315 ||| JJ
response  ||| S:13315 E:13324 ||| NN
of  ||| S:13324 E:13327 ||| IN
Cry1Aa  ||| S:13327 E:13334 ||| CD
with  ||| S:13334 E:13339 ||| IN
the  ||| S:13339 E:13343 ||| DT
binding  ||| S:13343 E:13351 ||| NN
of  ||| S:13351 E:13354 ||| IN
Cry1Ab ||| S:13354 E:13360 ||| NNP
,  ||| S:13360 E:13372 ||| ,
Cry1Ac ||| S:13372 E:13378 ||| NNP
,  ||| S:13378 E:13380 ||| ,
and  ||| S:13380 E:13384 ||| CC
domain-switched  ||| S:13384 E:13400 ||| JJ
toxin  ||| S:13400 E:13406 ||| NN
4109  ||| S:13406 E:13411 ||| CD
( ||| S:13411 E:13412 ||| -LRB-
Fig.  ||| S:13412 E:13417 ||| CD
7Aand  ||| S:13417 E:13423 ||| CD
7B ||| S:13423 E:13425 ||| CD
) ||| S:13425 E:13426 ||| -RRB-
.  ||| S:13426 E:13438 ||| .
Hybrid  ||| S:13438 E:13445 ||| JJ
toxin  ||| S:13445 E:13451 ||| NN
4109  ||| S:13451 E:13456 ||| CD
is  ||| S:13456 E:13459 ||| VBZ
particular  ||| S:13459 E:13470 ||| JJ
useful  ||| S:13470 E:13477 ||| JJ
in  ||| S:13477 E:13480 ||| IN
this  ||| S:13480 E:13485 ||| DT
context ||| S:13485 E:13492 ||| NN
,  ||| S:13492 E:13504 ||| ,
because  ||| S:13504 E:13512 ||| IN
it  ||| S:13512 E:13515 ||| PRP
is  ||| S:13515 E:13518 ||| VBZ
comprised  ||| S:13518 E:13528 ||| VBN
of  ||| S:13528 E:13531 ||| IN
domains  ||| S:13531 E:13539 ||| VBG
I  ||| S:13539 E:13541 ||| PRP
and  ||| S:13541 E:13545 ||| CC
II  ||| S:13545 E:13548 ||| NNP
from  ||| S:13548 E:13553 ||| IN
Cry1Aa  ||| S:13553 E:13570 ||| NNP
and  ||| S:13570 E:13574 ||| CC
domain  ||| S:13574 E:13581 ||| JJ
III  ||| S:13581 E:13585 ||| NNP
from  ||| S:13585 E:13590 ||| IN
Cry1Ac  ||| S:13590 E:13597 ||| NNP
( ||| S:13597 E:13598 ||| -LRB-
Aa ||| S:13598 E:13600 ||| NNP
/ ||| S:13600 E:13601 ||| NNP
Aa ||| S:13601 E:13603 ||| NNP
/ ||| S:13603 E:13604 ||| NNP
Ac ||| S:13604 E:13606 ||| NNP
)  ||| S:13606 E:13608 ||| -RRB-
[  ||| S:13608 E:13610 ||| -LRB-
3  ||| S:13610 E:13612 ||| LS
]  ||| S:13612 E:13614 ||| -RRB-
.  ||| S:13614 E:13626 ||| .
Hybrid-toxin  ||| S:13626 E:13639 ||| JJ
4109  ||| S:13639 E:13644 ||| CD
binding  ||| S:13644 E:13652 ||| NN
to  ||| S:13652 E:13655 ||| TO
both  ||| S:13655 E:13660 ||| DT
receptors  ||| S:13660 E:13670 ||| NN
was  ||| S:13670 E:13674 ||| VBD
not  ||| S:13674 E:13688 ||| RB
noticeably  ||| S:13688 E:13699 ||| RB
different  ||| S:13699 E:13709 ||| JJ
from  ||| S:13709 E:13714 ||| IN
Cry1Aa ||| S:13714 E:13720 ||| CD
:  ||| S:13720 E:13722 ||| :
for  ||| S:13722 E:13726 ||| IN
APN  ||| S:13726 E:13730 ||| NNP
binding ||| S:13730 E:13737 ||| NN
,  ||| S:13737 E:13750 ||| ,
k  ||| S:13750 E:13763 ||| VBG
a  ||| S:13763 E:13765 ||| DT
=  ||| S:13765 E:13767 ||| CD
1.9  ||| S:13767 E:13771 ||| CD
×  ||| S:13771 E:13773 ||| CD
10  ||| S:13773 E:13776 ||| CD
4M  ||| S:13776 E:13779 ||| CD
-1s  ||| S:13779 E:13783 ||| CD
-1 ||| S:13783 E:13785 ||| CD
( ||| S:13785 E:13786 ||| -LRB-
+ ||| S:13786 E:13787 ||| NNP
/ ||| S:13787 E:13788 ||| NNP
-  ||| S:13788 E:13790 ||| :
1.4  ||| S:13790 E:13794 ||| CD
×  ||| S:13794 E:13796 ||| CD
10  ||| S:13796 E:13809 ||| CD
2 ||| S:13809 E:13810 ||| CD
) ||| S:13810 E:13811 ||| -RRB-
,  ||| S:13811 E:13824 ||| ,
k  ||| S:13824 E:13837 ||| VBG
d  ||| S:13837 E:13839 ||| SYM
=  ||| S:13839 E:13841 ||| SYM
1.5  ||| S:13841 E:13845 ||| CD
×  ||| S:13845 E:13847 ||| CD
10  ||| S:13847 E:13850 ||| CD
-3s  ||| S:13850 E:13854 ||| CD
-1 ||| S:13854 E:13856 ||| CD
( ||| S:13856 E:13857 ||| -LRB-
+ ||| S:13857 E:13858 ||| NNP
/ ||| S:13858 E:13859 ||| NNP
-  ||| S:13859 E:13861 ||| :
1.6  ||| S:13861 E:13865 ||| CD
×  ||| S:13865 E:13867 ||| CD
10  ||| S:13867 E:13870 ||| CD
-5 ||| S:13870 E:13872 ||| CD
) ||| S:13872 E:13873 ||| -RRB-
,  ||| S:13873 E:13885 ||| ,
and  ||| S:13885 E:13900 ||| CC
K  ||| S:13900 E:13913 ||| NNP
D  ||| S:13913 E:13915 ||| NNP
=  ||| S:13915 E:13917 ||| SYM
78  ||| S:13917 E:13920 ||| CD
nM ||| S:13920 E:13922 ||| NN
;  ||| S:13922 E:13924 ||| :
for  ||| S:13924 E:13928 ||| IN
cadherin  ||| S:13928 E:13937 ||| JJ
binding ||| S:13937 E:13944 ||| NN
,  ||| S:13944 E:13957 ||| ,
k  ||| S:13957 E:13970 ||| VBG
a  ||| S:13970 E:13972 ||| DT
=  ||| S:13972 E:13974 ||| CD
1.3  ||| S:13974 E:13978 ||| CD
×  ||| S:13978 E:13980 ||| CD
10  ||| S:13980 E:13983 ||| CD
4M  ||| S:13983 E:13986 ||| CD
-1s  ||| S:13986 E:13990 ||| CD
-1 ||| S:13990 E:13992 ||| CD
( ||| S:13992 E:13993 ||| -LRB-
+ ||| S:13993 E:13994 ||| NNP
/ ||| S:13994 E:13995 ||| NNP
-  ||| S:13995 E:13997 ||| :
2  ||| S:13997 E:13999 ||| CD
×  ||| S:13999 E:14001 ||| CD
10  ||| S:14001 E:14004 ||| CD
2 ||| S:14004 E:14005 ||| CD
) ||| S:14005 E:14006 ||| -RRB-
,  ||| S:14006 E:14019 ||| ,
k  ||| S:14019 E:14032 ||| VBG
d  ||| S:14032 E:14034 ||| SYM
=  ||| S:14034 E:14036 ||| SYM
3.34  ||| S:14036 E:14041 ||| CD
×  ||| S:14041 E:14043 ||| CD
10  ||| S:14043 E:14046 ||| CD
-5s  ||| S:14046 E:14050 ||| CD
-1 ||| S:14050 E:14052 ||| CD
( ||| S:14052 E:14053 ||| -LRB-
+ ||| S:14053 E:14054 ||| NNP
/ ||| S:14054 E:14055 ||| NNP
-  ||| S:14055 E:14057 ||| :
2  ||| S:14057 E:14059 ||| CD
×  ||| S:14059 E:14061 ||| CD
10  ||| S:14061 E:14064 ||| CD
-5 ||| S:14064 E:14066 ||| CD
) ||| S:14066 E:14067 ||| -RRB-
,  ||| S:14067 E:14079 ||| ,
and  ||| S:14079 E:14094 ||| CC
K  ||| S:14094 E:14107 ||| NNP
D  ||| S:14107 E:14109 ||| NNP
=  ||| S:14109 E:14111 ||| SYM
2.6  ||| S:14111 E:14115 ||| CD
nM ||| S:14115 E:14117 ||| NN
.  ||| S:14117 E:14119 ||| .
In  ||| S:14119 E:14122 ||| IN
stark  ||| S:14122 E:14128 ||| JJ
contrast ||| S:14128 E:14136 ||| NN
,  ||| S:14136 E:14138 ||| ,
Cry1Ab  ||| S:14138 E:14155 ||| NNP
and  ||| S:14155 E:14159 ||| CC
Cry1Ac  ||| S:14159 E:14166 ||| NNP
showed  ||| S:14166 E:14173 ||| VBD
no  ||| S:14173 E:14176 ||| DT
apparent  ||| S:14176 E:14185 ||| JJ
binding  ||| S:14185 E:14193 ||| NN
to  ||| S:14193 E:14196 ||| TO
either  ||| S:14196 E:14203 ||| DT
receptor  ||| S:14203 E:14222 ||| NN
( ||| S:14222 E:14223 ||| -LRB-
Fig.  ||| S:14223 E:14228 ||| CD
7Aand  ||| S:14228 E:14234 ||| CD
7B ||| S:14234 E:14236 ||| CD
) ||| S:14236 E:14237 ||| -RRB-
.  ||| S:14237 E:14239 ||| .
These  ||| S:14239 E:14245 ||| DT
results  ||| S:14245 E:14253 ||| NNS
are  ||| S:14253 E:14257 ||| VBP
entirely  ||| S:14257 E:14266 ||| RB
consistent  ||| S:14266 E:14287 ||| JJ
with  ||| S:14287 E:14292 ||| IN
the  ||| S:14292 E:14296 ||| DT
hypothesis  ||| S:14296 E:14307 ||| NN
that  ||| S:14307 E:14312 ||| IN
Cry1Aa  ||| S:14312 E:14319 ||| CD
domain  ||| S:14319 E:14326 ||| NN
II  ||| S:14326 E:14329 ||| NNP
( ||| S:14329 E:14330 ||| -LRB-
alone ||| S:14330 E:14335 ||| RB
)  ||| S:14335 E:14337 ||| -RRB-
is  ||| S:14337 E:14350 ||| VBZ
essential  ||| S:14350 E:14360 ||| JJ
for  ||| S:14360 E:14364 ||| IN
binding  ||| S:14364 E:14372 ||| VBG
to  ||| S:14372 E:14375 ||| TO
both  ||| S:14375 E:14380 ||| PDT
the  ||| S:14380 E:14384 ||| DT
APN  ||| S:14384 E:14388 ||| NNP
and  ||| S:14388 E:14392 ||| CC
cadherin-like  ||| S:14392 E:14416 ||| JJ
receptors  ||| S:14416 E:14426 ||| NNS
as  ||| S:14426 E:14429 ||| IN
purified  ||| S:14429 E:14438 ||| NN
in  ||| S:14438 E:14441 ||| IN
the  ||| S:14441 E:14445 ||| DT
present  ||| S:14445 E:14453 ||| JJ
study ||| S:14453 E:14458 ||| NN
.  ||| S:14458 E:14491 ||| .
Discussion  ||| S:14491 E:14510 ||| NN
The  ||| S:14510 E:14514 ||| DT
dissociation  ||| S:14514 E:14527 ||| JJ
constants  ||| S:14527 E:14537 ||| JJ
presented  ||| S:14537 E:14547 ||| NNS
are  ||| S:14547 E:14551 ||| VBP
the  ||| S:14551 E:14555 ||| DT
first  ||| S:14555 E:14569 ||| JJ
determined  ||| S:14569 E:14580 ||| VBN
for  ||| S:14580 E:14593 ||| IN
B.  ||| S:14593 E:14596 ||| NNP
mori  ||| S:14596 E:14601 ||| FW
Cry  ||| S:14601 E:14605 ||| FW
receptors  ||| S:14605 E:14615 ||| FW
by  ||| S:14615 E:14618 ||| IN
the  ||| S:14618 E:14622 ||| DT
use  ||| S:14622 E:14626 ||| NN
of  ||| S:14626 E:14637 ||| IN
SPR  ||| S:14637 E:14641 ||| NNP
technology ||| S:14641 E:14651 ||| NN
.  ||| S:14651 E:14653 ||| .
Additionally ||| S:14653 E:14665 ||| RB
,  ||| S:14665 E:14667 ||| ,
the  ||| S:14667 E:14671 ||| DT
apparent  ||| S:14671 E:14680 ||| JJ
affinity  ||| S:14680 E:14689 ||| NN
of  ||| S:14689 E:14700 ||| IN
Cry1Aa  ||| S:14700 E:14707 ||| CD
for  ||| S:14707 E:14711 ||| IN
the  ||| S:14711 E:14715 ||| DT
cadherin-like  ||| S:14715 E:14729 ||| JJ
receptor  ||| S:14729 E:14738 ||| NN
is  ||| S:14738 E:14741 ||| VBZ
the  ||| S:14741 E:14745 ||| DT
highest  ||| S:14745 E:14761 ||| JJS
observed  ||| S:14761 E:14770 ||| JJ
affinity  ||| S:14770 E:14779 ||| NN
to  ||| S:14779 E:14782 ||| TO
date  ||| S:14782 E:14787 ||| NN
for  ||| S:14787 E:14791 ||| IN
Cry  ||| S:14791 E:14795 ||| NNP
toxin  ||| S:14795 E:14801 ||| NN
binding  ||| S:14801 E:14809 ||| VBG
to  ||| S:14809 E:14812 ||| TO
purified  ||| S:14812 E:14829 ||| VB
receptors  ||| S:14829 E:14839 ||| VBN
using  ||| S:14839 E:14845 ||| VBG
SPR ||| S:14845 E:14848 ||| NNP
.  ||| S:14848 E:14850 ||| .
This  ||| S:14850 E:14855 ||| DT
finding  ||| S:14855 E:14863 ||| NN
emphasizes  ||| S:14863 E:14874 ||| VBZ
the  ||| S:14874 E:14878 ||| DT
important  ||| S:14878 E:14896 ||| JJ
biological  ||| S:14896 E:14907 ||| JJ
role  ||| S:14907 E:14912 ||| NN
that  ||| S:14912 E:14917 ||| IN
this  ||| S:14917 E:14922 ||| DT
receptor  ||| S:14922 E:14931 ||| NN
class  ||| S:14931 E:14937 ||| NN
plays  ||| S:14937 E:14943 ||| VBZ
for  ||| S:14943 E:14947 ||| IN
Bt  ||| S:14947 E:14958 ||| NNP
toxins ||| S:14958 E:14964 ||| NN
.  ||| S:14964 E:14966 ||| .
Recently ||| S:14966 E:14974 ||| RB
,  ||| S:14974 E:14976 ||| ,
using  ||| S:14976 E:14982 ||| VBG
phage  ||| S:14982 E:14988 ||| JJ
display  ||| S:14988 E:14996 ||| NN
technology ||| S:14996 E:15006 ||| NN
,  ||| S:15006 E:15008 ||| ,
a  ||| S:15008 E:15010 ||| DT
scFv  ||| S:15010 E:15023 ||| JJ
molecule  ||| S:15023 E:15032 ||| NN
with  ||| S:15032 E:15037 ||| IN
short  ||| S:15037 E:15043 ||| JJ
sequence  ||| S:15043 E:15052 ||| NN
homology  ||| S:15052 E:15061 ||| NN
to  ||| S:15061 E:15073 ||| TO
M.  ||| S:15073 E:15076 ||| NNP
sexta  ||| S:15076 E:15082 ||| NN
and  ||| S:15082 E:15095 ||| CC
B.  ||| S:15095 E:15098 ||| NNP
mori  ||| S:15098 E:15103 ||| VBD
cadherin-like  ||| S:15103 E:15117 ||| JJ
receptors  ||| S:15117 E:15127 ||| NNS
was  ||| S:15127 E:15139 ||| VBD
shown  ||| S:15139 E:15145 ||| VBN
to  ||| S:15145 E:15148 ||| TO
bind  ||| S:15148 E:15153 ||| VB
domain  ||| S:15153 E:15160 ||| JJ
II  ||| S:15160 E:15163 ||| NNP
of  ||| S:15163 E:15166 ||| IN
Cry1Aa ||| S:15166 E:15172 ||| NNP
,  ||| S:15172 E:15174 ||| ,
Cry1Ab ||| S:15174 E:15180 ||| NNP
,  ||| S:15180 E:15182 ||| ,
and  ||| S:15182 E:15186 ||| CC
Cry1Ac  ||| S:15186 E:15201 ||| CD
toxins  ||| S:15201 E:15208 ||| NNS
[  ||| S:15208 E:15210 ||| -LRB-
20  ||| S:15210 E:15213 ||| CD
]  ||| S:15213 E:15215 ||| -RRB-
.  ||| S:15215 E:15217 ||| .
In  ||| S:15217 E:15220 ||| IN
the  ||| S:15220 E:15224 ||| DT
present  ||| S:15224 E:15232 ||| JJ
study ||| S:15232 E:15237 ||| NN
,  ||| S:15237 E:15239 ||| ,
only  ||| S:15239 E:15244 ||| RB
Cry1Aa  ||| S:15244 E:15251 ||| CD
shows  ||| S:15251 E:15265 ||| NNS
measurable  ||| S:15265 E:15276 ||| VBP
binding  ||| S:15276 E:15284 ||| VBG
to  ||| S:15284 E:15287 ||| TO
the  ||| S:15287 E:15291 ||| DT
purified ||| S:15291 E:15299 ||| NN
,  ||| S:15299 E:15301 ||| ,
native  ||| S:15301 E:15308 ||| JJ
cadherin-like  ||| S:15308 E:15330 ||| JJ
receptor  ||| S:15330 E:15339 ||| NN
from  ||| S:15339 E:15353 ||| IN
B.  ||| S:15353 E:15356 ||| NNP
mori  ||| S:15356 E:15361 ||| NN
.  ||| S:15361 E:15363 ||| .
This  ||| S:15363 E:15368 ||| DT
finding  ||| S:15368 E:15376 ||| NN
may  ||| S:15376 E:15380 ||| MD
be  ||| S:15380 E:15383 ||| VB
the  ||| S:15383 E:15395 ||| DT
result  ||| S:15395 E:15402 ||| NN
of  ||| S:15402 E:15405 ||| IN
purification  ||| S:15405 E:15418 ||| NN
of  ||| S:15418 E:15421 ||| IN
a  ||| S:15421 E:15423 ||| DT
particular  ||| S:15423 E:15434 ||| JJ
receptor  ||| S:15434 E:15443 ||| NN
variant  ||| S:15443 E:15459 ||| NN
with  ||| S:15459 E:15464 ||| IN
Cry1Aa  ||| S:15464 E:15471 ||| CD
specificity  ||| S:15471 E:15483 ||| NNS
( ||| S:15483 E:15484 ||| -LRB-
e.g. ||| S:15484 E:15488 ||| NNP
,  ||| S:15488 E:15490 ||| ,
one  ||| S:15490 E:15494 ||| CD
of  ||| S:15494 E:15497 ||| IN
potentially  ||| S:15497 E:15509 ||| RB
several  ||| S:15509 E:15525 ||| JJ
glycosylated  ||| S:15525 E:15538 ||| JJ
isoforms ||| S:15538 E:15546 ||| NN
) ||| S:15546 E:15547 ||| -RRB-
.  ||| S:15547 E:15549 ||| .
Alternatively ||| S:15549 E:15562 ||| RB
,  ||| S:15562 E:15564 ||| ,
it  ||| S:15564 E:15567 ||| PRP
may  ||| S:15567 E:15571 ||| MD
reflect  ||| S:15571 E:15587 ||| VB
greater  ||| S:15587 E:15595 ||| JJR
specificity  ||| S:15595 E:15607 ||| NN
of  ||| S:15607 E:15610 ||| IN
Cry1Aa  ||| S:15610 E:15617 ||| CD
domain  ||| S:15617 E:15624 ||| NN
II  ||| S:15624 E:15627 ||| NNP
for  ||| S:15627 E:15631 ||| IN
neighboring  ||| S:15631 E:15651 ||| JJ
residues  ||| S:15651 E:15660 ||| NNS
on  ||| S:15660 E:15663 ||| IN
the  ||| S:15663 E:15676 ||| DT
B.  ||| S:15676 E:15679 ||| NNP
mori  ||| S:15679 E:15684 ||| VBD
cadherin-like  ||| S:15684 E:15698 ||| JJ
receptor  ||| S:15698 E:15707 ||| NN
beyond  ||| S:15707 E:15722 ||| IN
the  ||| S:15722 E:15726 ||| DT
conserved  ||| S:15726 E:15736 ||| JJ
Cry1A-toxin  ||| S:15736 E:15748 ||| CD
binding  ||| S:15748 E:15756 ||| JJ
segment ||| S:15756 E:15763 ||| NN
,  ||| S:15763 E:15765 ||| ,
which  ||| S:15765 E:15771 ||| WDT
might  ||| S:15771 E:15777 ||| MD
be  ||| S:15777 E:15788 ||| VB
absent  ||| S:15788 E:15795 ||| VBN
in  ||| S:15795 E:15798 ||| IN
smaller  ||| S:15798 E:15806 ||| JJR
peptide  ||| S:15806 E:15814 ||| JJ
sequences ||| S:15814 E:15823 ||| NN
.  ||| S:15823 E:15833 ||| .
The  ||| S:15833 E:15837 ||| DT
apparent  ||| S:15837 E:15846 ||| JJ
Cry1Aa  ||| S:15846 E:15853 ||| CD
affinity  ||| S:15853 E:15862 ||| NN
for  ||| S:15862 E:15866 ||| IN
purified  ||| S:15866 E:15875 ||| JJ
APN  ||| S:15875 E:15879 ||| NNS
measured  ||| S:15879 E:15896 ||| VBN
in  ||| S:15896 E:15899 ||| IN
this  ||| S:15899 E:15904 ||| DT
study ||| S:15904 E:15909 ||| NN
,  ||| S:15909 E:15911 ||| ,
75  ||| S:15911 E:15914 ||| CD
nM ||| S:15914 E:15916 ||| NN
,  ||| S:15916 E:15918 ||| ,
is  ||| S:15918 E:15921 ||| VBZ
10-fold  ||| S:15921 E:15929 ||| JJ
higher  ||| S:15929 E:15936 ||| JJR
than  ||| S:15936 E:15941 ||| IN
the  ||| S:15941 E:15945 ||| DT
value  ||| S:15945 E:15959 ||| NN
reported  ||| S:15959 E:15968 ||| VBD
by  ||| S:15968 E:15971 ||| IN
Yaoi  ||| S:15971 E:15985 ||| NNP
et  ||| S:15985 E:15988 ||| FW
al.  ||| S:15988 E:15992 ||| FW
[  ||| S:15992 E:15994 ||| -LRB-
6  ||| S:15994 E:15996 ||| CD
]  ||| S:15996 E:15998 ||| -RRB-
for  ||| S:15998 E:16002 ||| IN
purified  ||| S:16002 E:16011 ||| JJ
110-kDa  ||| S:16011 E:16019 ||| NNP
APN  ||| S:16019 E:16031 ||| NNP
using  ||| S:16031 E:16037 ||| VBG
a  ||| S:16037 E:16039 ||| DT
separate  ||| S:16039 E:16048 ||| JJ
technique  ||| S:16048 E:16058 ||| NN
( ||| S:16058 E:16059 ||| -LRB-
7.6  ||| S:16059 E:16063 ||| CD
nM ||| S:16063 E:16065 ||| NN
) ||| S:16065 E:16066 ||| -RRB-
.  ||| S:16066 E:16068 ||| .
In  ||| S:16068 E:16071 ||| IN
the  ||| S:16071 E:16075 ||| DT
aforementioned  ||| S:16075 E:16098 ||| JJ
study ||| S:16098 E:16103 ||| NN
,  ||| S:16103 E:16105 ||| ,
an  ||| S:16105 E:16108 ||| DT
ELISA  ||| S:16108 E:16114 ||| NNP
assay  ||| S:16114 E:16120 ||| NN
was  ||| S:16120 E:16124 ||| VBD
used  ||| S:16124 E:16129 ||| VBN
to  ||| S:16129 E:16132 ||| TO
indirectly  ||| S:16132 E:16143 ||| RB
calculate  ||| S:16143 E:16161 ||| VB
affinity  ||| S:16161 E:16170 ||| VBN
by  ||| S:16170 E:16173 ||| IN
incubating  ||| S:16173 E:16184 ||| JJ
receptor-bound  ||| S:16184 E:16199 ||| JJ
toxin  ||| S:16199 E:16205 ||| NN
with  ||| S:16205 E:16210 ||| IN
a  ||| S:16210 E:16220 ||| DT
peroxidase-conjugated  ||| S:16220 E:16242 ||| JJ
anti-Cry1Aa  ||| S:16242 E:16254 ||| CD
antibody  ||| S:16254 E:16263 ||| NN
over  ||| S:16263 E:16268 ||| IN
1.5  ||| S:16268 E:16272 ||| CD
hours  ||| S:16272 E:16286 ||| NNS
at  ||| S:16286 E:16289 ||| IN
37°C ||| S:16289 E:16293 ||| CD
.  ||| S:16293 E:16295 ||| .
It  ||| S:16295 E:16298 ||| PRP
is  ||| S:16298 E:16301 ||| VBZ
possible  ||| S:16301 E:16310 ||| JJ
that  ||| S:16310 E:16315 ||| IN
the  ||| S:16315 E:16319 ||| DT
difference  ||| S:16319 E:16330 ||| NN
in  ||| S:16330 E:16333 ||| IN
binding  ||| S:16333 E:16349 ||| JJ
constants  ||| S:16349 E:16359 ||| NN
reflects  ||| S:16359 E:16368 ||| VBZ
our  ||| S:16368 E:16372 ||| PRP$
condition  ||| S:16372 E:16382 ||| NN
of  ||| S:16382 E:16385 ||| IN
more  ||| S:16385 E:16390 ||| RBR
direct  ||| S:16390 E:16405 ||| JJ
receptor-binding  ||| S:16405 E:16422 ||| JJ
measurement  ||| S:16422 E:16434 ||| NN
in  ||| S:16434 E:16437 ||| IN
"real-time ||| S:16437 E:16447 ||| NNP
" ||| S:16447 E:16448 ||| ''
,  ||| S:16448 E:16450 ||| ,
as  ||| S:16450 E:16453 ||| RB
well  ||| S:16453 E:16458 ||| RB
as  ||| S:16458 E:16461 ||| IN
the  ||| S:16461 E:16473 ||| DT
different  ||| S:16473 E:16483 ||| JJ
binding  ||| S:16483 E:16491 ||| JJ
buffers  ||| S:16491 E:16499 ||| NN
and  ||| S:16499 E:16503 ||| CC
temperature  ||| S:16503 E:16515 ||| NN
used ||| S:16515 E:16519 ||| VBN
.  ||| S:16519 E:16529 ||| .
Yaoi  ||| S:16529 E:16543 ||| FW
et  ||| S:16543 E:16546 ||| FW
al.  ||| S:16546 E:16550 ||| FW
[  ||| S:16550 E:16552 ||| -LRB-
21  ||| S:16552 E:16555 ||| CD
]  ||| S:16555 E:16557 ||| -RRB-
estimated  ||| S:16557 E:16567 ||| VBD
the  ||| S:16567 E:16579 ||| DT
toxin-binding  ||| S:16579 E:16593 ||| JJ
region  ||| S:16593 E:16600 ||| NN
of  ||| S:16600 E:16612 ||| IN
B.  ||| S:16612 E:16615 ||| NNP
mori  ||| S:16615 E:16620 ||| VBD
APN  ||| S:16620 E:16624 ||| NNP
to  ||| S:16624 E:16627 ||| TO
be  ||| S:16627 E:16630 ||| VB
between  ||| S:16630 E:16638 ||| IN
Ile135  ||| S:16638 E:16645 ||| NNP
and  ||| S:16645 E:16657 ||| CC
Pro198  ||| S:16657 E:16664 ||| RB
based  ||| S:16664 E:16670 ||| VBN
on  ||| S:16670 E:16673 ||| IN
toxin  ||| S:16673 E:16679 ||| NN
blot  ||| S:16679 E:16684 ||| NN
overlays  ||| S:16684 E:16693 ||| NN
with  ||| S:16693 E:16698 ||| IN
protease-digested  ||| S:16698 E:16724 ||| NNP
APN  ||| S:16724 E:16728 ||| NNP
fragments ||| S:16728 E:16737 ||| NNS
.  ||| S:16737 E:16739 ||| .
BLAST  ||| S:16739 E:16745 ||| NN
sequence  ||| S:16745 E:16754 ||| NN
alignments  ||| S:16754 E:16765 ||| NNS
[  ||| S:16765 E:16767 ||| -LRB-
22  ||| S:16767 E:16770 ||| CD
]  ||| S:16770 E:16772 ||| -RRB-
yielded  ||| S:16772 E:16780 ||| VBD
81 ||| S:16780 E:16782 ||| CD
%  ||| S:16782 E:16792 ||| NN
identity  ||| S:16792 E:16801 ||| NN
and  ||| S:16801 E:16805 ||| CC
96 ||| S:16805 E:16807 ||| CD
%  ||| S:16807 E:16809 ||| NN
similarity  ||| S:16809 E:16820 ||| NN
between  ||| S:16820 E:16828 ||| IN
this  ||| S:16828 E:16833 ||| DT
63  ||| S:16833 E:16836 ||| CD
residue  ||| S:16836 E:16844 ||| JJ
stretch  ||| S:16844 E:16860 ||| NN
and  ||| S:16860 E:16864 ||| CC
the  ||| S:16864 E:16868 ||| DT
homologous  ||| S:16868 E:16879 ||| JJ
region  ||| S:16879 E:16886 ||| NN
of  ||| S:16886 E:16898 ||| IN
M.  ||| S:16898 E:16901 ||| NNP
sexta  ||| S:16901 E:16907 ||| VBD
APN-1 ||| S:16907 E:16912 ||| CD
,  ||| S:16912 E:16914 ||| ,
which  ||| S:16914 E:16920 ||| WDT
also  ||| S:16920 E:16925 ||| RB
binds  ||| S:16925 E:16939 ||| CD
Cry1Aa  ||| S:16939 E:16946 ||| CD
toxin  ||| S:16946 E:16952 ||| NN
( ||| S:16952 E:16953 ||| -LRB-
Jenkins ||| S:16953 E:16960 ||| NNP
,  ||| S:16960 E:16962 ||| ,
unpublished  ||| S:16962 E:16974 ||| JJ
observation ||| S:16974 E:16985 ||| NN
) ||| S:16985 E:16986 ||| -RRB-
.  ||| S:16986 E:16996 ||| .
Interestingly ||| S:16996 E:17009 ||| RB
,  ||| S:17009 E:17011 ||| ,
in  ||| S:17011 E:17023 ||| IN
L.  ||| S:17023 E:17026 ||| NNP
dispar  ||| S:17026 E:17033 ||| VBD
APN-1 ||| S:17033 E:17038 ||| CD
,  ||| S:17038 E:17040 ||| ,
which  ||| S:17040 E:17046 ||| WDT
does  ||| S:17046 E:17051 ||| VBZ
not  ||| S:17051 E:17055 ||| RB
bind  ||| S:17055 E:17068 ||| CD
Cry1Aa ||| S:17068 E:17074 ||| CD
,  ||| S:17074 E:17076 ||| ,
the  ||| S:17076 E:17080 ||| DT
same  ||| S:17080 E:17085 ||| JJ
stretch  ||| S:17085 E:17093 ||| NN
is  ||| S:17093 E:17096 ||| VBZ
only  ||| S:17096 E:17101 ||| RB
37 ||| S:17101 E:17103 ||| CD
%  ||| S:17103 E:17105 ||| NN
identical  ||| S:17105 E:17115 ||| NNS
and  ||| S:17115 E:17119 ||| CC
56 ||| S:17119 E:17121 ||| CD
%  ||| S:17121 E:17131 ||| NN
similar  ||| S:17131 E:17139 ||| JJ
( ||| S:17139 E:17140 ||| -LRB-
4 ||| S:17140 E:17141 ||| CD
%  ||| S:17141 E:17143 ||| NN
unaligned  ||| S:17143 E:17153 ||| NN
gaps ||| S:17153 E:17157 ||| NN
) ||| S:17157 E:17158 ||| -RRB-
.  ||| S:17158 E:17160 ||| .
These  ||| S:17160 E:17166 ||| DT
results  ||| S:17166 E:17174 ||| NNS
appear  ||| S:17174 E:17181 ||| VBP
to  ||| S:17181 E:17192 ||| TO
support  ||| S:17192 E:17200 ||| VB
the  ||| S:17200 E:17204 ||| DT
findings  ||| S:17204 E:17213 ||| NNS
of  ||| S:17213 E:17216 ||| IN
Yaoi  ||| S:17216 E:17230 ||| NNP
et  ||| S:17230 E:17233 ||| FW
al.  ||| S:17233 E:17237 ||| FW
[  ||| S:17237 E:17239 ||| -LRB-
21  ||| S:17239 E:17242 ||| CD
]  ||| S:17242 E:17244 ||| -RRB-
.  ||| S:17244 E:17246 ||| .
However ||| S:17246 E:17253 ||| RB
,  ||| S:17253 E:17264 ||| ,
Heliothis  ||| S:17264 E:17274 ||| NNP
virescens  ||| S:17274 E:17284 ||| NNS
( ||| S:17284 E:17285 ||| -LRB-
tobacco  ||| S:17285 E:17293 ||| NN
budworm ||| S:17293 E:17300 ||| NN
)  ||| S:17300 E:17310 ||| -RRB-
APN  ||| S:17310 E:17314 ||| NNP
is  ||| S:17314 E:17317 ||| VBZ
only  ||| S:17317 E:17322 ||| RB
45 ||| S:17322 E:17324 ||| CD
%  ||| S:17324 E:17326 ||| NN
identical  ||| S:17326 E:17336 ||| NNS
and  ||| S:17336 E:17340 ||| CC
53 ||| S:17340 E:17342 ||| CD
%  ||| S:17342 E:17344 ||| NN
similar  ||| S:17344 E:17352 ||| JJ
to  ||| S:17352 E:17364 ||| TO
B.  ||| S:17364 E:17367 ||| NNP
mori  ||| S:17367 E:17372 ||| VBD
APN ||| S:17372 E:17375 ||| NNP
,  ||| S:17375 E:17377 ||| ,
yet  ||| S:17377 E:17381 ||| RB
it  ||| S:17381 E:17384 ||| PRP
binds  ||| S:17384 E:17390 ||| VBD
Cry1Aa  ||| S:17390 E:17405 ||| CD
toxin  ||| S:17405 E:17411 ||| NN
with  ||| S:17411 E:17416 ||| IN
high  ||| S:17416 E:17421 ||| JJ
affinity  ||| S:17421 E:17430 ||| NNS
[  ||| S:17430 E:17432 ||| -LRB-
23  ||| S:17432 E:17435 ||| CD
]  ||| S:17435 E:17437 ||| -RRB-
.  ||| S:17437 E:17439 ||| .
Moreover ||| S:17439 E:17447 ||| RB
,  ||| S:17447 E:17449 ||| ,
sequence  ||| S:17449 E:17466 ||| JJ
alignments  ||| S:17466 E:17477 ||| NN
with  ||| S:17477 E:17482 ||| IN
APN  ||| S:17482 E:17486 ||| NNP
from  ||| S:17486 E:17500 ||| IN
Lactobacillus  ||| S:17500 E:17514 ||| NNP
,  ||| S:17514 E:17525 ||| ,
Streptococcus  ||| S:17525 E:17539 ||| NNP
,  ||| S:17539 E:17550 ||| ,
Saccharomyces  ||| S:17550 E:17564 ||| NNP
,  ||| S:17564 E:17575 ||| ,
Arabidopsis  ||| S:17575 E:17587 ||| NNP
,  ||| S:17587 E:17589 ||| ,
rat ||| S:17589 E:17592 ||| NN
,  ||| S:17592 E:17594 ||| ,
pig ||| S:17594 E:17597 ||| NN
,  ||| S:17597 E:17599 ||| ,
yeast ||| S:17599 E:17604 ||| NN
,  ||| S:17604 E:17606 ||| ,
and  ||| S:17606 E:17618 ||| CC
human  ||| S:17618 E:17624 ||| JJ
yielded  ||| S:17624 E:17632 ||| NN
more  ||| S:17632 E:17637 ||| JJR
similarity  ||| S:17637 E:17648 ||| NN
than  ||| S:17648 E:17662 ||| IN
H.  ||| S:17662 E:17665 ||| NNP
virescens  ||| S:17665 E:17675 ||| VBD
APN  ||| S:17675 E:17679 ||| NNP
to  ||| S:17679 E:17682 ||| TO
the  ||| S:17682 E:17686 ||| DT
putative  ||| S:17686 E:17703 ||| JJ
Cry1Aa-binding  ||| S:17703 E:17718 ||| CD
region  ||| S:17718 E:17725 ||| NN
of  ||| S:17725 E:17737 ||| IN
B.  ||| S:17737 E:17740 ||| NNP
mori  ||| S:17740 E:17745 ||| VBD
APN ||| S:17745 E:17748 ||| NNP
.  ||| S:17748 E:17750 ||| .
It  ||| S:17750 E:17753 ||| PRP
is  ||| S:17753 E:17756 ||| VBZ
likely  ||| S:17756 E:17763 ||| RB
that  ||| S:17763 E:17768 ||| IN
as  ||| S:17768 E:17771 ||| IN
the  ||| S:17771 E:17783 ||| DT
X-ray  ||| S:17783 E:17789 ||| NN
crystal  ||| S:17789 E:17797 ||| NN
structures  ||| S:17797 E:17808 ||| NNS
of  ||| S:17808 E:17811 ||| IN
APNs  ||| S:17811 E:17816 ||| NNS
are  ||| S:17816 E:17820 ||| VBP
solved ||| S:17820 E:17826 ||| VBN
,  ||| S:17826 E:17828 ||| ,
structural  ||| S:17828 E:17847 ||| JJ
alignments  ||| S:17847 E:17858 ||| NN
of  ||| S:17858 E:17861 ||| IN
APNs  ||| S:17861 E:17866 ||| NNP
will  ||| S:17866 E:17871 ||| MD
help  ||| S:17871 E:17876 ||| VB
resolve  ||| S:17876 E:17884 ||| VB
the  ||| S:17884 E:17896 ||| DT
specificity-determining  ||| S:17896 E:17920 ||| JJ
regions  ||| S:17920 E:17928 ||| NNS
more  ||| S:17928 E:17933 ||| RBR
accurately ||| S:17933 E:17943 ||| RB
.  ||| S:17943 E:17953 ||| .
Additionally ||| S:17953 E:17965 ||| RB
,  ||| S:17965 E:17967 ||| ,
structural  ||| S:17967 E:17978 ||| JJ
information  ||| S:17978 E:17990 ||| NN
will  ||| S:17990 E:17995 ||| MD
aid  ||| S:17995 E:17999 ||| VB
in  ||| S:17999 E:18002 ||| IN
the  ||| S:18002 E:18014 ||| DT
rational  ||| S:18014 E:18023 ||| JJ
construction  ||| S:18023 E:18036 ||| NN
of  ||| S:18036 E:18039 ||| IN
toxins  ||| S:18039 E:18046 ||| NN
with  ||| S:18046 E:18051 ||| IN
reduced  ||| S:18051 E:18059 ||| JJ
binding  ||| S:18059 E:18067 ||| NN
for  ||| S:18067 E:18079 ||| IN
beneficial  ||| S:18079 E:18090 ||| JJ
insects  ||| S:18090 E:18098 ||| NNS
without  ||| S:18098 E:18106 ||| IN
losing  ||| S:18106 E:18113 ||| VBG
activity  ||| S:18113 E:18122 ||| NN
to  ||| S:18122 E:18125 ||| TO
target  ||| S:18125 E:18132 ||| VB
pests ||| S:18132 E:18137 ||| NNS
.  ||| S:18137 E:18147 ||| .
In  ||| S:18147 E:18150 ||| IN
this  ||| S:18150 E:18155 ||| DT
context  ||| S:18155 E:18163 ||| NN
a  ||| S:18163 E:18165 ||| DT
unique  ||| S:18165 E:18172 ||| JJ
Cry1Aa  ||| S:18172 E:18179 ||| FW
binding  ||| S:18179 E:18187 ||| FW
epitope  ||| S:18187 E:18195 ||| FW
within  ||| S:18195 E:18210 ||| FW
domain  ||| S:18210 E:18217 ||| FW
II  ||| S:18217 E:18220 ||| NNP
has  ||| S:18220 E:18224 ||| VBZ
been  ||| S:18224 E:18229 ||| VBN
identified  ||| S:18229 E:18240 ||| VBN
that ||| S:18240 E:18244 ||| IN
,  ||| S:18244 E:18246 ||| ,
when  ||| S:18246 E:18251 ||| WRB
mutated ||| S:18251 E:18258 ||| NNS
,  ||| S:18258 E:18260 ||| ,
results  ||| S:18260 E:18276 ||| NNS
in  ||| S:18276 E:18279 ||| IN
specific  ||| S:18279 E:18288 ||| JJ
reduction  ||| S:18288 E:18298 ||| NN
of  ||| S:18298 E:18301 ||| IN
toxicity  ||| S:18301 E:18310 ||| VBG
to  ||| S:18310 E:18322 ||| TO
B.  ||| S:18322 E:18325 ||| NNP
mori  ||| S:18325 E:18330 ||| NNS
( ||| S:18330 E:18331 ||| -LRB-
You ||| S:18331 E:18334 ||| PRP
,  ||| S:18334 E:18336 ||| ,
et  ||| S:18336 E:18339 ||| FW
al. ||| S:18339 E:18342 ||| FW
,  ||| S:18342 E:18344 ||| ,
unpublished  ||| S:18344 E:18364 ||| JJ
manuscript ||| S:18364 E:18374 ||| NN
) ||| S:18374 E:18375 ||| -RRB-
.  ||| S:18375 E:18377 ||| .
The  ||| S:18377 E:18381 ||| DT
application  ||| S:18381 E:18393 ||| NN
of  ||| S:18393 E:18396 ||| IN
protein  ||| S:18396 E:18404 ||| NN
engineering  ||| S:18404 E:18416 ||| NN
to  ||| S:18416 E:18428 ||| TO
B.  ||| S:18428 E:18431 ||| NNP
thuringiensis  ||| S:18431 E:18445 ||| FW
insecticidal  ||| S:18445 E:18466 ||| FW
proteins  ||| S:18466 E:18475 ||| FW
is  ||| S:18475 E:18478 ||| VBZ
entering  ||| S:18478 E:18487 ||| VBG
a  ||| S:18487 E:18489 ||| DT
new  ||| S:18489 E:18493 ||| JJ
era  ||| S:18493 E:18497 ||| NN
of  ||| S:18497 E:18500 ||| IN
tailoring  ||| S:18500 E:18510 ||| JJ
pesticides  ||| S:18510 E:18521 ||| NNS
with  ||| S:18521 E:18534 ||| IN
reduced  ||| S:18534 E:18542 ||| JJ
activity  ||| S:18542 E:18551 ||| NN
to  ||| S:18551 E:18554 ||| TO
beneficial  ||| S:18554 E:18565 ||| JJ
insects  ||| S:18565 E:18573 ||| NNS
as  ||| S:18573 E:18576 ||| IN
well  ||| S:18576 E:18581 ||| RB
as  ||| S:18581 E:18592 ||| IN
increasing  ||| S:18592 E:18603 ||| VBG
activity  ||| S:18603 E:18612 ||| NN
against  ||| S:18612 E:18620 ||| IN
pest  ||| S:18620 E:18625 ||| JJ
insects  ||| S:18625 E:18633 ||| NNS
[  ||| S:18633 E:18635 ||| -LRB-
24  ||| S:18635 E:18638 ||| CD
]  ||| S:18638 E:18640 ||| -RRB-
.  ||| S:18640 E:18664 ||| .
Conclusions  ||| S:18664 E:18684 ||| NNP
Domain  ||| S:18684 E:18691 ||| NNP
II  ||| S:18691 E:18694 ||| NNP
of  ||| S:18694 E:18697 ||| IN
Cry1Aa  ||| S:18697 E:18704 ||| NNP
is  ||| S:18704 E:18707 ||| VBZ
both  ||| S:18707 E:18712 ||| DT
necessary  ||| S:18712 E:18722 ||| JJ
and  ||| S:18722 E:18726 ||| CC
essential  ||| S:18726 E:18736 ||| JJ
for  ||| S:18736 E:18748 ||| IN
tight  ||| S:18748 E:18754 ||| JJ
binding  ||| S:18754 E:18762 ||| NN
to  ||| S:18762 E:18765 ||| TO
two  ||| S:18765 E:18778 ||| CD
B.  ||| S:18778 E:18781 ||| NNP
mori  ||| S:18781 E:18786 ||| FW
midgut  ||| S:18786 E:18793 ||| FW
receptors ||| S:18793 E:18802 ||| FW
,  ||| S:18802 E:18804 ||| ,
the  ||| S:18804 E:18816 ||| DT
cadherin-like  ||| S:18816 E:18830 ||| JJ
and  ||| S:18830 E:18834 ||| CC
aminopeptidase  ||| S:18834 E:18849 ||| JJ
N  ||| S:18849 E:18851 ||| NNP
receptors ||| S:18851 E:18860 ||| NNS
,  ||| S:18860 E:18862 ||| ,
a  ||| S:18862 E:18864 ||| DT
finding  ||| S:18864 E:18880 ||| NN
that  ||| S:18880 E:18885 ||| IN
correlates  ||| S:18885 E:18896 ||| NN
with  ||| S:18896 E:18901 ||| IN
biological  ||| S:18901 E:18912 ||| JJ
activity  ||| S:18912 E:18921 ||| NN
data ||| S:18921 E:18925 ||| NNS
.  ||| S:18925 E:18927 ||| .
The  ||| S:18927 E:18931 ||| DT
Cry1Aa  ||| S:18931 E:18946 ||| JJ
binding  ||| S:18946 E:18954 ||| JJ
affinity ||| S:18954 E:18962 ||| NN
,  ||| S:18962 E:18964 ||| ,
as  ||| S:18964 E:18967 ||| RB
well  ||| S:18967 E:18972 ||| RB
as  ||| S:18972 E:18975 ||| IN
the  ||| S:18975 E:18979 ||| DT
dissociation  ||| S:18979 E:18992 ||| JJ
rate  ||| S:18992 E:18997 ||| NN
for  ||| S:18997 E:19001 ||| IN
the  ||| S:19001 E:19013 ||| DT
cadherin-like  ||| S:19013 E:19027 ||| JJ
receptor ||| S:19027 E:19035 ||| NN
,  ||| S:19035 E:19037 ||| ,
are  ||| S:19037 E:19041 ||| VBP
the  ||| S:19041 E:19045 ||| DT
lowest  ||| S:19045 E:19052 ||| JJS
measured  ||| S:19052 E:19061 ||| VBN
using  ||| S:19061 E:19067 ||| VBG
the  ||| S:19067 E:19079 ||| DT
surface  ||| S:19079 E:19087 ||| NN
plasmon  ||| S:19087 E:19095 ||| NN
resonance  ||| S:19095 E:19105 ||| NN
technique ||| S:19105 E:19114 ||| NN
.  ||| S:19114 E:19116 ||| .
The  ||| S:19116 E:19120 ||| DT
SPR  ||| S:19120 E:19124 ||| NNP
method  ||| S:19124 E:19139 ||| NN
presented  ||| S:19139 E:19149 ||| VBD
here  ||| S:19149 E:19154 ||| RB
may  ||| S:19154 E:19158 ||| MD
be  ||| S:19158 E:19161 ||| VB
useful  ||| S:19161 E:19168 ||| JJ
for  ||| S:19168 E:19172 ||| IN
screening  ||| S:19172 E:19182 ||| VBG
other  ||| S:19182 E:19188 ||| JJ
Cry  ||| S:19188 E:19192 ||| JJ
toxins  ||| S:19192 E:19207 ||| NN
or  ||| S:19207 E:19210 ||| CC
Cry  ||| S:19210 E:19214 ||| NNP
toxin  ||| S:19214 E:19220 ||| NN
variants  ||| S:19220 E:19229 ||| VBZ
specifically  ||| S:19229 E:19242 ||| RB
engineered  ||| S:19242 E:19253 ||| VBN
to  ||| S:19253 E:19256 ||| TO
reduce  ||| S:19256 E:19263 ||| VB
or  ||| S:19263 E:19274 ||| CC
eliminate  ||| S:19274 E:19284 ||| VB
specificity  ||| S:19284 E:19296 ||| VBN
for  ||| S:19296 E:19300 ||| IN
receptors  ||| S:19300 E:19310 ||| NNS
from  ||| S:19310 E:19315 ||| IN
this  ||| S:19315 E:19320 ||| DT
non-target  ||| S:19320 E:19339 ||| JJ
insect ||| S:19339 E:19345 ||| NN
.  ||| S:19345 E:19369 ||| .
Materials  ||| S:19369 E:19379 ||| NNS
and  ||| S:19379 E:19383 ||| CC
methods  ||| S:19383 E:19410 ||| NNS
Mutant  ||| S:19410 E:19417 ||| JJ
toxin  ||| S:19417 E:19423 ||| NN
construction  ||| S:19423 E:19436 ||| NN
and  ||| S:19436 E:19440 ||| CC
preliminary  ||| S:19440 E:19462 ||| JJ
analysis  ||| S:19462 E:19481 ||| NN
Hybrid  ||| S:19481 E:19488 ||| NNP
toxin  ||| S:19488 E:19494 ||| NN
4109  ||| S:19494 E:19499 ||| CD
consisting  ||| S:19499 E:19510 ||| NN
of  ||| S:19510 E:19513 ||| IN
domains  ||| S:19513 E:19521 ||| VBG
I  ||| S:19521 E:19523 ||| PRP
and  ||| S:19523 E:19527 ||| CC
II  ||| S:19527 E:19530 ||| NNP
of  ||| S:19530 E:19543 ||| IN
Cry1Aa  ||| S:19543 E:19550 ||| NNP
and  ||| S:19550 E:19554 ||| CC
domain  ||| S:19554 E:19561 ||| JJ
III  ||| S:19561 E:19565 ||| NNP
of  ||| S:19565 E:19568 ||| IN
Cry1Ac  ||| S:19568 E:19575 ||| NNP
was  ||| S:19575 E:19579 ||| VBD
constructed  ||| S:19579 E:19591 ||| VBN
as  ||| S:19591 E:19604 ||| IN
previously  ||| S:19604 E:19615 ||| RB
described  ||| S:19615 E:19625 ||| VBN
[  ||| S:19625 E:19627 ||| -LRB-
3  ||| S:19627 E:19629 ||| LS
]  ||| S:19629 E:19631 ||| -RRB-
.  ||| S:19631 E:19633 ||| .
Force-feeding  ||| S:19633 E:19647 ||| JJ
bioassays  ||| S:19647 E:19657 ||| NN
on  ||| S:19657 E:19671 ||| IN
B.  ||| S:19671 E:19674 ||| NNP
mori  ||| S:19674 E:19679 ||| NN
and  ||| S:19679 E:19683 ||| CC
BBMV  ||| S:19683 E:19688 ||| NNP
binding  ||| S:19688 E:19696 ||| JJ
assays  ||| S:19696 E:19713 ||| NN
were  ||| S:19713 E:19718 ||| VBD
conducted  ||| S:19718 E:19728 ||| VBN
as  ||| S:19728 E:19731 ||| RB
described  ||| S:19731 E:19741 ||| VBN
[  ||| S:19741 E:19743 ||| -LRB-
4  ||| S:19743 E:19745 ||| LS
]  ||| S:19745 E:19747 ||| -RRB-
.  ||| S:19747 E:19749 ||| .
Crystal  ||| S:19749 E:19757 ||| NN
proteins  ||| S:19757 E:19766 ||| NNS
were  ||| S:19766 E:19781 ||| VBD
solubilized  ||| S:19781 E:19793 ||| JJ
and  ||| S:19793 E:19797 ||| CC
trypsinized ||| S:19797 E:19808 ||| NN
,  ||| S:19808 E:19810 ||| ,
and  ||| S:19810 E:19814 ||| CC
active  ||| S:19814 E:19821 ||| JJ
toxins  ||| S:19821 E:19828 ||| NN
were  ||| S:19828 E:19843 ||| VBD
column  ||| S:19843 E:19850 ||| NN
purified  ||| S:19850 E:19859 ||| VBZ
as  ||| S:19859 E:19862 ||| RB
carried  ||| S:19862 E:19870 ||| VBN
out  ||| S:19870 E:19874 ||| RP
previously  ||| S:19874 E:19885 ||| RB
[  ||| S:19885 E:19887 ||| -LRB-
19  ||| S:19887 E:19890 ||| CD
]  ||| S:19890 E:19892 ||| -RRB-
.  ||| S:19892 E:19922 ||| .
Receptor  ||| S:19922 E:19931 ||| NNP
purification  ||| S:19931 E:19965 ||| VBD
B.  ||| S:19965 E:19968 ||| NNP
mori  ||| S:19968 E:19973 ||| NN
midguts  ||| S:19973 E:19981 ||| NNS
were  ||| S:19981 E:19986 ||| VBD
dissected  ||| S:19986 E:19996 ||| VBN
from  ||| S:19996 E:20011 ||| IN
4  ||| S:20011 E:20013 ||| CD
thor  ||| S:20013 E:20018 ||| CD
5  ||| S:20018 E:20020 ||| CD
thinstar  ||| S:20020 E:20029 ||| CD
larvae  ||| S:20029 E:20036 ||| NNS
and  ||| S:20036 E:20040 ||| CC
brush  ||| S:20040 E:20046 ||| JJ
border  ||| S:20046 E:20053 ||| NN
membrane  ||| S:20053 E:20072 ||| NN
vesicles  ||| S:20072 E:20081 ||| NNS
were  ||| S:20081 E:20086 ||| VBD
prepared  ||| S:20086 E:20095 ||| VBN
by  ||| S:20095 E:20098 ||| IN
the  ||| S:20098 E:20102 ||| DT
Wolfersberger  ||| S:20102 E:20116 ||| JJ
method  ||| S:20116 E:20123 ||| NN
[  ||| S:20123 E:20125 ||| -LRB-
25  ||| S:20125 E:20128 ||| CD
]  ||| S:20128 E:20140 ||| -RRB-
.  ||| S:20140 E:20153 ||| .
B.  ||| S:20153 E:20156 ||| NNP
mori  ||| S:20156 E:20161 ||| FW
BBMV  ||| S:20161 E:20166 ||| FW
( ||| S:20166 E:20167 ||| -LRB-
10  ||| S:20167 E:20170 ||| CD
mg  ||| S:20170 E:20173 ||| NN
in  ||| S:20173 E:20176 ||| IN
10  ||| S:20176 E:20179 ||| CD
ml ||| S:20179 E:20181 ||| CD
)  ||| S:20181 E:20183 ||| -RRB-
was  ||| S:20183 E:20197 ||| VBD
solubilized  ||| S:20197 E:20209 ||| VBN
in  ||| S:20209 E:20212 ||| IN
5  ||| S:20212 E:20214 ||| CD
mg ||| S:20214 E:20216 ||| FW
/ ||| S:20216 E:20217 ||| FW
ml  ||| S:20217 E:20220 ||| FW
CHAPS  ||| S:20220 E:20226 ||| FW
zwitterionic  ||| S:20226 E:20239 ||| FW
detergent  ||| S:20239 E:20259 ||| FW
( ||| S:20259 E:20260 ||| -LRB-
Roche ||| S:20260 E:20265 ||| NNP
)  ||| S:20265 E:20267 ||| -RRB-
overnight  ||| S:20267 E:20277 ||| JJ
at  ||| S:20277 E:20280 ||| IN
4  ||| S:20280 E:20282 ||| CD
oC  ||| S:20282 E:20285 ||| NN
with  ||| S:20285 E:20290 ||| IN
gentle  ||| S:20290 E:20297 ||| JJ
rocking ||| S:20297 E:20304 ||| NN
.  ||| S:20304 E:20316 ||| .
Solubilized  ||| S:20316 E:20328 ||| NNP
BBMV  ||| S:20328 E:20333 ||| NNP
was  ||| S:20333 E:20337 ||| VBD
centrifuged  ||| S:20337 E:20349 ||| VBN
at  ||| S:20349 E:20352 ||| IN
10,000  ||| S:20352 E:20359 ||| CD
×  ||| S:20359 E:20361 ||| CD
g  ||| S:20361 E:20363 ||| NN
for  ||| S:20363 E:20367 ||| IN
10  ||| S:20367 E:20370 ||| CD
min  ||| S:20370 E:20384 ||| NNS
and  ||| S:20384 E:20388 ||| CC
supernatant  ||| S:20388 E:20400 ||| NNS
was  ||| S:20400 E:20404 ||| VBD
concentrated  ||| S:20404 E:20417 ||| VBN
to  ||| S:20417 E:20420 ||| TO
2  ||| S:20420 E:20422 ||| CD
ml  ||| S:20422 E:20425 ||| NN
by  ||| S:20425 E:20428 ||| IN
Amicon  ||| S:20428 E:20435 ||| NNP
YM30  ||| S:20435 E:20450 ||| NNP
ultrafiltration ||| S:20450 E:20465 ||| NN
.  ||| S:20465 E:20467 ||| .
The  ||| S:20467 E:20471 ||| DT
sample  ||| S:20471 E:20478 ||| NN
was  ||| S:20478 E:20482 ||| VBD
then  ||| S:20482 E:20487 ||| RB
loaded  ||| S:20487 E:20494 ||| VBN
on  ||| S:20494 E:20497 ||| IN
a  ||| S:20497 E:20499 ||| DT
Q  ||| S:20499 E:20511 ||| NNP
Sepharose  ||| S:20511 E:20521 ||| NNP
HR  ||| S:20521 E:20524 ||| NNP
10 ||| S:20524 E:20526 ||| CD
/ ||| S:20526 E:20527 ||| CD
30  ||| S:20527 E:20530 ||| CD
anion-exchange  ||| S:20530 E:20545 ||| JJ
column ||| S:20545 E:20551 ||| NN
.  ||| S:20551 E:20553 ||| .
All  ||| S:20553 E:20557 ||| DT
column  ||| S:20557 E:20574 ||| NN
chromatography  ||| S:20574 E:20589 ||| NNS
was  ||| S:20589 E:20593 ||| VBD
carried  ||| S:20593 E:20601 ||| VBN
out  ||| S:20601 E:20605 ||| RP
on  ||| S:20605 E:20608 ||| IN
an  ||| S:20608 E:20611 ||| DT
ÄKTA  ||| S:20611 E:20616 ||| NNP
Explorer  ||| S:20616 E:20635 ||| NNP
( ||| S:20635 E:20636 ||| -LRB-
Amersham  ||| S:20636 E:20645 ||| NNP
Pharmacia  ||| S:20645 E:20655 ||| NNP
Biotech ||| S:20655 E:20662 ||| NNP
) ||| S:20662 E:20663 ||| -RRB-
.  ||| S:20663 E:20665 ||| .
Low  ||| S:20665 E:20669 ||| JJ
salt  ||| S:20669 E:20674 ||| NN
buffer  ||| S:20674 E:20681 ||| NN
( ||| S:20681 E:20682 ||| -LRB-
buffer  ||| S:20682 E:20689 ||| VB
A ||| S:20689 E:20690 ||| DT
)  ||| S:20690 E:20702 ||| -RRB-
consisted  ||| S:20702 E:20712 ||| VBD
of  ||| S:20712 E:20715 ||| IN
20  ||| S:20715 E:20718 ||| CD
mM  ||| S:20718 E:20721 ||| JJ
Tris ||| S:20721 E:20725 ||| NNP
,  ||| S:20725 E:20727 ||| ,
5  ||| S:20727 E:20729 ||| CD
mM  ||| S:20729 E:20732 ||| JJ
MgCl ||| S:20732 E:20736 ||| NN
,  ||| S:20736 E:20738 ||| ,
0.4  ||| S:20738 E:20742 ||| CD
mg ||| S:20742 E:20744 ||| CD
/ ||| S:20744 E:20745 ||| CD
ml  ||| S:20745 E:20748 ||| JJ
CHAPS ||| S:20748 E:20753 ||| NNP
,  ||| S:20753 E:20755 ||| ,
pH  ||| S:20755 E:20768 ||| JJ
8.6 ||| S:20768 E:20771 ||| CD
,  ||| S:20771 E:20773 ||| ,
and  ||| S:20773 E:20777 ||| CC
the  ||| S:20777 E:20781 ||| DT
high  ||| S:20781 E:20786 ||| JJ
salt  ||| S:20786 E:20791 ||| NN
buffer  ||| S:20791 E:20798 ||| NN
used  ||| S:20798 E:20803 ||| VBN
was  ||| S:20803 E:20807 ||| VBD
buffer  ||| S:20807 E:20814 ||| VBN
A  ||| S:20814 E:20826 ||| DT
containing  ||| S:20826 E:20837 ||| VBG
1  ||| S:20837 E:20839 ||| CD
M  ||| S:20839 E:20841 ||| NNP
NaCl ||| S:20841 E:20845 ||| NNP
.  ||| S:20845 E:20847 ||| .
A  ||| S:20847 E:20849 ||| DT
step  ||| S:20849 E:20854 ||| NN
gradient  ||| S:20854 E:20863 ||| NN
of  ||| S:20863 E:20866 ||| IN
salt  ||| S:20866 E:20871 ||| NN
was  ||| S:20871 E:20875 ||| VBD
used  ||| S:20875 E:20880 ||| VBN
to  ||| S:20880 E:20893 ||| TO
elute  ||| S:20893 E:20899 ||| VB
BBMV  ||| S:20899 E:20904 ||| JJ
proteins ||| S:20904 E:20912 ||| NNS
.  ||| S:20912 E:20914 ||| .
All  ||| S:20914 E:20918 ||| DT
fractions  ||| S:20918 E:20928 ||| NN
were  ||| S:20928 E:20933 ||| VBD
tested  ||| S:20933 E:20940 ||| VBN
for  ||| S:20940 E:20944 ||| IN
APN  ||| S:20944 E:20958 ||| NNP
enzymatic  ||| S:20958 E:20968 ||| JJ
activity  ||| S:20968 E:20977 ||| NN
by  ||| S:20977 E:20980 ||| IN
the  ||| S:20980 E:20984 ||| DT
LpNA  ||| S:20984 E:20989 ||| JJ
assay ||| S:20989 E:20994 ||| NN
.  ||| S:20994 E:20996 ||| .
Briefly ||| S:20996 E:21003 ||| RB
,  ||| S:21003 E:21005 ||| ,
390  ||| S:21005 E:21009 ||| CD
μl  ||| S:21009 E:21012 ||| NN
of  ||| S:21012 E:21025 ||| IN
sample  ||| S:21025 E:21032 ||| NNS
are  ||| S:21032 E:21036 ||| VBP
mixed  ||| S:21036 E:21042 ||| VBN
with  ||| S:21042 E:21047 ||| IN
10  ||| S:21047 E:21050 ||| CD
μl  ||| S:21050 E:21053 ||| NN
of  ||| S:21053 E:21056 ||| IN
2  ||| S:21056 E:21058 ||| CD
mM  ||| S:21058 E:21071 ||| JJ
leucine-p-nitroanilide  ||| S:21071 E:21094 ||| NN
( ||| S:21094 E:21095 ||| -LRB-
containing  ||| S:21095 E:21106 ||| VBG
a  ||| S:21106 E:21118 ||| DT
leucine-phenylalanine  ||| S:21118 E:21140 ||| JJ
dipeptide ||| S:21140 E:21149 ||| NN
) ||| S:21149 E:21150 ||| -RRB-
.  ||| S:21150 E:21152 ||| .
A  ||| S:21152 E:21154 ||| DT
yellow  ||| S:21154 E:21161 ||| JJ
chromophoric  ||| S:21161 E:21184 ||| JJ
change  ||| S:21184 E:21191 ||| NN
indicates  ||| S:21191 E:21201 ||| VBZ
aminopeptidase  ||| S:21201 E:21216 ||| JJ
N  ||| S:21216 E:21218 ||| NNP
activity ||| S:21218 E:21226 ||| NN
,  ||| S:21226 E:21228 ||| ,
defined  ||| S:21228 E:21236 ||| VBN
as  ||| S:21236 E:21249 ||| IN
the  ||| S:21249 E:21253 ||| DT
ability  ||| S:21253 E:21261 ||| NN
to  ||| S:21261 E:21264 ||| TO
cleave  ||| S:21264 E:21271 ||| VB
a  ||| S:21271 E:21273 ||| DT
neutral  ||| S:21273 E:21281 ||| JJ
amino  ||| S:21281 E:21287 ||| JJ
acid  ||| S:21287 E:21292 ||| NN
from  ||| S:21292 E:21297 ||| IN
the  ||| S:21297 E:21311 ||| DT
N-terminus  ||| S:21311 E:21322 ||| JJ
of  ||| S:21322 E:21325 ||| IN
a  ||| S:21325 E:21327 ||| DT
polypeptide ||| S:21327 E:21338 ||| NN
.  ||| S:21338 E:21340 ||| .
Cry1Aa  ||| S:21340 E:21347 ||| NNP
binding  ||| S:21347 E:21355 ||| JJ
ability  ||| S:21355 E:21363 ||| NN
was  ||| S:21363 E:21377 ||| VBD
also  ||| S:21377 E:21382 ||| RB
checked  ||| S:21382 E:21390 ||| VBN
by  ||| S:21390 E:21393 ||| IN
slot  ||| S:21393 E:21398 ||| NN
blotting  ||| S:21398 E:21407 ||| VBG
fractions  ||| S:21407 E:21417 ||| NNS
to  ||| S:21417 E:21420 ||| TO
PVDF  ||| S:21420 E:21425 ||| NNP
membrane  ||| S:21425 E:21444 ||| NN
and  ||| S:21444 E:21448 ||| CC
probing  ||| S:21448 E:21456 ||| VBG
with  ||| S:21456 E:21461 ||| IN
biotinylated  ||| S:21461 E:21474 ||| CD
Cry1Aa  ||| S:21474 E:21481 ||| CD
[  ||| S:21481 E:21483 ||| -LRB-
26  ||| S:21483 E:21486 ||| CD
]  ||| S:21486 E:21488 ||| -RRB-
.  ||| S:21488 E:21490 ||| .
Fractions  ||| S:21490 E:21510 ||| NNS
with  ||| S:21510 E:21515 ||| IN
Cry1Aa-binding  ||| S:21515 E:21530 ||| CD
ability  ||| S:21530 E:21538 ||| NN
and  ||| S:21538 E:21542 ||| CC
APN  ||| S:21542 E:21546 ||| NNP
enzymatic  ||| S:21546 E:21556 ||| JJ
activity  ||| S:21556 E:21575 ||| NN
were  ||| S:21575 E:21580 ||| VBD
concentrated  ||| S:21580 E:21593 ||| VBN
to  ||| S:21593 E:21596 ||| TO
2  ||| S:21596 E:21598 ||| CD
ml  ||| S:21598 E:21601 ||| CD
volumes  ||| S:21601 E:21609 ||| NNS
and  ||| S:21609 E:21613 ||| CC
loaded  ||| S:21613 E:21620 ||| VBN
on  ||| S:21620 E:21623 ||| IN
a  ||| S:21623 E:21635 ||| DT
Superdex  ||| S:21635 E:21644 ||| NNP
200  ||| S:21644 E:21648 ||| CD
size-exclusion  ||| S:21648 E:21663 ||| JJ
column  ||| S:21663 E:21670 ||| NN
( ||| S:21670 E:21671 ||| -LRB-
120  ||| S:21671 E:21675 ||| CD
ml  ||| S:21675 E:21678 ||| JJ
bed  ||| S:21678 E:21682 ||| NN
volume ||| S:21682 E:21688 ||| NN
)  ||| S:21688 E:21700 ||| -RRB-
using  ||| S:21700 E:21706 ||| VBG
Hepes-buffered  ||| S:21706 E:21721 ||| JJ
saline  ||| S:21721 E:21728 ||| NNS
( ||| S:21728 E:21729 ||| -LRB-
HBS ||| S:21729 E:21732 ||| NNP
;  ||| S:21732 E:21734 ||| :
10  ||| S:21734 E:21737 ||| CD
mM  ||| S:21737 E:21740 ||| JJ
Hepes ||| S:21740 E:21745 ||| NNP
,  ||| S:21745 E:21747 ||| ,
150  ||| S:21747 E:21751 ||| CD
mM  ||| S:21751 E:21764 ||| JJ
NaCl ||| S:21764 E:21768 ||| NN
,  ||| S:21768 E:21770 ||| ,
3.4  ||| S:21770 E:21774 ||| CD
mM  ||| S:21774 E:21777 ||| JJ
EDTA ||| S:21777 E:21781 ||| NNP
,  ||| S:21781 E:21783 ||| ,
pH  ||| S:21783 E:21786 ||| JJ
7.4 ||| S:21786 E:21789 ||| CD
)  ||| S:21789 E:21791 ||| -RRB-
as  ||| S:21791 E:21794 ||| IN
running  ||| S:21794 E:21802 ||| VBG
buffer ||| S:21802 E:21808 ||| NN
.  ||| S:21808 E:21810 ||| .
Absorbance  ||| S:21810 E:21831 ||| NNP
was  ||| S:21831 E:21835 ||| VBD
monitored  ||| S:21835 E:21845 ||| VBN
at  ||| S:21845 E:21848 ||| IN
280  ||| S:21848 E:21852 ||| CD
nm  ||| S:21852 E:21855 ||| NNS
and  ||| S:21855 E:21859 ||| CC
260  ||| S:21859 E:21863 ||| CD
nm  ||| S:21863 E:21866 ||| NN
to  ||| S:21866 E:21869 ||| TO
judge  ||| S:21869 E:21875 ||| VB
protein  ||| S:21875 E:21893 ||| NN
purity  ||| S:21893 E:21900 ||| NN
of  ||| S:21900 E:21903 ||| IN
collected  ||| S:21903 E:21913 ||| JJ
peaks  ||| S:21913 E:21919 ||| NNS
relative  ||| S:21919 E:21928 ||| JJ
to  ||| S:21928 E:21931 ||| TO
flow  ||| S:21931 E:21936 ||| VB
through ||| S:21936 E:21943 ||| RP
.  ||| S:21943 E:21955 ||| .
Fractions  ||| S:21955 E:21965 ||| JJ
eluting  ||| S:21965 E:21973 ||| NN
around  ||| S:21973 E:21980 ||| IN
115-120  ||| S:21980 E:21988 ||| NNP
kDa ||| S:21988 E:21991 ||| NNP
,  ||| S:21991 E:21993 ||| ,
the  ||| S:21993 E:21997 ||| DT
MW  ||| S:21997 E:22000 ||| NNP
of  ||| S:22000 E:22003 ||| IN
APN ||| S:22003 E:22006 ||| NNP
,  ||| S:22006 E:22008 ||| ,
were  ||| S:22008 E:22023 ||| VBD
collected  ||| S:22023 E:22033 ||| VBN
and  ||| S:22033 E:22037 ||| CC
protease  ||| S:22037 E:22046 ||| JJ
inhibitors  ||| S:22046 E:22057 ||| NN
were  ||| S:22057 E:22062 ||| VBD
added  ||| S:22062 E:22068 ||| VBN
after  ||| S:22068 E:22074 ||| IN
a  ||| S:22074 E:22086 ||| DT
final  ||| S:22086 E:22092 ||| JJ
concentration ||| S:22092 E:22105 ||| NN
.  ||| S:22105 E:22107 ||| .
Anion-exchange  ||| S:22107 E:22122 ||| JJ
fractions  ||| S:22122 E:22132 ||| NNS
with  ||| S:22132 E:22147 ||| IN
Cry1Aa-binding  ||| S:22147 E:22162 ||| CD
ability  ||| S:22162 E:22170 ||| NN
but  ||| S:22170 E:22174 ||| CC
without  ||| S:22174 E:22182 ||| IN
APN  ||| S:22182 E:22186 ||| NNP
enzymatic  ||| S:22186 E:22196 ||| JJ
activity  ||| S:22196 E:22215 ||| NN
were  ||| S:22215 E:22220 ||| VBD
also  ||| S:22220 E:22225 ||| RB
size-purifed ||| S:22225 E:22237 ||| JJ
,  ||| S:22237 E:22239 ||| ,
and  ||| S:22239 E:22243 ||| CC
fractions  ||| S:22243 E:22253 ||| JJ
eluting  ||| S:22253 E:22261 ||| NN
around  ||| S:22261 E:22278 ||| IN
175-250  ||| S:22278 E:22286 ||| NNP
kDa ||| S:22286 E:22289 ||| NNP
,  ||| S:22289 E:22291 ||| ,
the  ||| S:22291 E:22295 ||| DT
MW  ||| S:22295 E:22298 ||| NNP
of  ||| S:22298 E:22301 ||| IN
BtR175 ||| S:22301 E:22307 ||| NNP
,  ||| S:22307 E:22309 ||| ,
were  ||| S:22309 E:22314 ||| VBD
collected  ||| S:22314 E:22324 ||| VBN
and  ||| S:22324 E:22338 ||| CC
concentrated ||| S:22338 E:22350 ||| JJ
.  ||| S:22350 E:22352 ||| .
Approximately  ||| S:22352 E:22366 ||| RB
0.10  ||| S:22366 E:22371 ||| CD
mg  ||| S:22371 E:22374 ||| NNS
( ||| S:22374 E:22375 ||| -LRB-
in  ||| S:22375 E:22378 ||| IN
0.25  ||| S:22378 E:22383 ||| CD
ml ||| S:22383 E:22385 ||| CD
)  ||| S:22385 E:22387 ||| -RRB-
of  ||| S:22387 E:22400 ||| IN
cadherin-like  ||| S:22400 E:22414 ||| JJ
receptor  ||| S:22414 E:22423 ||| NN
and  ||| S:22423 E:22427 ||| CC
0.30  ||| S:22427 E:22432 ||| CD
mg  ||| S:22432 E:22435 ||| NN
of  ||| S:22435 E:22438 ||| IN
APN  ||| S:22438 E:22442 ||| NNP
( ||| S:22442 E:22443 ||| -LRB-
in  ||| S:22443 E:22446 ||| IN
1  ||| S:22446 E:22448 ||| CD
ml ||| S:22448 E:22450 ||| CD
)  ||| S:22450 E:22452 ||| -RRB-
were  ||| S:22452 E:22467 ||| VBD
obtained ||| S:22467 E:22475 ||| VBN
.  ||| S:22475 E:22505 ||| .
Analysis  ||| S:22505 E:22514 ||| NN
of  ||| S:22514 E:22517 ||| IN
receptor  ||| S:22517 E:22526 ||| FW
purity  ||| S:22526 E:22543 ||| FW
Candidate  ||| S:22543 E:22553 ||| FW
receptor  ||| S:22553 E:22562 ||| FW
fractions  ||| S:22562 E:22572 ||| NNS
were  ||| S:22572 E:22577 ||| VBD
analyzed  ||| S:22577 E:22586 ||| VBN
by  ||| S:22586 E:22589 ||| IN
10 ||| S:22589 E:22591 ||| CD
%  ||| S:22591 E:22603 ||| NN
SDS-PAGE  ||| S:22603 E:22612 ||| NNS
( ||| S:22612 E:22613 ||| -LRB-
40  ||| S:22613 E:22616 ||| CD
μl ||| S:22616 E:22618 ||| CD
/ ||| S:22618 E:22619 ||| CD
lane ||| S:22619 E:22623 ||| CD
)  ||| S:22623 E:22625 ||| -RRB-
and  ||| S:22625 E:22629 ||| CC
stained  ||| S:22629 E:22637 ||| NN
with  ||| S:22637 E:22642 ||| IN
Coomassie  ||| S:22642 E:22662 ||| NNP
brilliant  ||| S:22662 E:22672 ||| JJ
blue ||| S:22672 E:22676 ||| NN
.  ||| S:22676 E:22678 ||| .
For  ||| S:22678 E:22682 ||| IN
slot  ||| S:22682 E:22687 ||| JJ
blot  ||| S:22687 E:22692 ||| JJ
assays ||| S:22692 E:22698 ||| NN
,  ||| S:22698 E:22700 ||| ,
5  ||| S:22700 E:22702 ||| CD
μg  ||| S:22702 E:22705 ||| NN
of  ||| S:22705 E:22719 ||| IN
M.  ||| S:22719 E:22722 ||| NNP
sexta  ||| S:22722 E:22728 ||| NN
or  ||| S:22728 E:22742 ||| CC
B.  ||| S:22742 E:22745 ||| NNP
mori  ||| S:22745 E:22750 ||| VBD
BBMVs  ||| S:22750 E:22756 ||| JJ
and  ||| S:22756 E:22760 ||| CC
40  ||| S:22760 E:22763 ||| CD
μl  ||| S:22763 E:22766 ||| NN
of  ||| S:22766 E:22779 ||| IN
candidate  ||| S:22779 E:22789 ||| NN
receptor  ||| S:22789 E:22798 ||| NN
fractions  ||| S:22798 E:22808 ||| NNS
were  ||| S:22808 E:22813 ||| VBD
blotted  ||| S:22813 E:22821 ||| VBN
onto  ||| S:22821 E:22826 ||| IN
PVDF  ||| S:22826 E:22841 ||| NNP
membrane  ||| S:22841 E:22850 ||| NN
and  ||| S:22850 E:22854 ||| CC
assays  ||| S:22854 E:22861 ||| NNS
was  ||| S:22861 E:22865 ||| VBD
carried  ||| S:22865 E:22873 ||| VBN
out  ||| S:22873 E:22877 ||| RP
as  ||| S:22877 E:22880 ||| RB
reported  ||| S:22880 E:22899 ||| VBD
previously  ||| S:22899 E:22910 ||| RB
[  ||| S:22910 E:22912 ||| -LRB-
27  ||| S:22912 E:22915 ||| CD
]  ||| S:22915 E:22917 ||| -RRB-
,  ||| S:22917 E:22919 ||| ,
except  ||| S:22919 E:22926 ||| IN
for  ||| S:22926 E:22930 ||| IN
using  ||| S:22930 E:22936 ||| VBG
1 ||| S:22936 E:22937 ||| CD
: ||| S:22937 E:22938 ||| :
1000  ||| S:22938 E:22943 ||| CD
anti-Bt-R  ||| S:22943 E:22964 ||| JJ
1  ||| S:22964 E:22966 ||| CD
polyclonal  ||| S:22966 E:22977 ||| CD
antiserum ||| S:22977 E:22986 ||| NNS
.  ||| S:22986 E:22988 ||| .
For  ||| S:22988 E:22992 ||| IN
ligand  ||| S:22992 E:23009 ||| JJ
blot  ||| S:23009 E:23014 ||| JJ
assays ||| S:23014 E:23020 ||| NN
,  ||| S:23020 E:23022 ||| ,
samples  ||| S:23022 E:23030 ||| NNS
separated  ||| S:23030 E:23040 ||| VBN
by  ||| S:23040 E:23043 ||| IN
SDS-PAGE  ||| S:23043 E:23052 ||| NNP
( ||| S:23052 E:23053 ||| -LRB-
9 ||| S:23053 E:23054 ||| CD
% ||| S:23054 E:23055 ||| NN
)  ||| S:23055 E:23057 ||| -RRB-
were  ||| S:23057 E:23072 ||| VBD
transferred  ||| S:23072 E:23084 ||| VBN
to  ||| S:23084 E:23087 ||| TO
PVDF  ||| S:23087 E:23092 ||| NNP
overnight ||| S:23092 E:23101 ||| JJ
,  ||| S:23101 E:23103 ||| ,
blocked  ||| S:23103 E:23111 ||| VBN
with  ||| S:23111 E:23116 ||| IN
5 ||| S:23116 E:23117 ||| CD
%  ||| S:23117 E:23119 ||| NN
dried  ||| S:23119 E:23125 ||| VBD
milk  ||| S:23125 E:23140 ||| NN
in  ||| S:23140 E:23143 ||| IN
TTBS  ||| S:23143 E:23148 ||| NNP
( ||| S:23148 E:23149 ||| -LRB-
50  ||| S:23149 E:23152 ||| CD
mM  ||| S:23152 E:23155 ||| JJ
Tris-HCl ||| S:23155 E:23163 ||| NN
,  ||| S:23163 E:23165 ||| ,
150  ||| S:23165 E:23169 ||| CD
mM  ||| S:23169 E:23172 ||| JJ
NaCl ||| S:23172 E:23176 ||| NN
,  ||| S:23176 E:23178 ||| ,
0.05 ||| S:23178 E:23182 ||| CD
%  ||| S:23182 E:23184 ||| NN
Tween  ||| S:23184 E:23190 ||| NNP
20 ||| S:23190 E:23192 ||| CD
,  ||| S:23192 E:23194 ||| ,
pH  ||| S:23194 E:23207 ||| JJ
7.5 ||| S:23207 E:23210 ||| CD
) ||| S:23210 E:23211 ||| -RRB-
.  ||| S:23211 E:23213 ||| .
Samples  ||| S:23213 E:23221 ||| NNS
were  ||| S:23221 E:23226 ||| VBD
probed  ||| S:23226 E:23233 ||| VBN
with  ||| S:23233 E:23238 ||| IN
50  ||| S:23238 E:23241 ||| CD
μg  ||| S:23241 E:23244 ||| CD
biotin-Cry1Aa  ||| S:23244 E:23258 ||| CD
and  ||| S:23258 E:23272 ||| CC
streptavidin-conjugated  ||| S:23272 E:23296 ||| JJ
horseradish  ||| S:23296 E:23308 ||| JJ
peroxidase  ||| S:23308 E:23319 ||| NN
for  ||| S:23319 E:23323 ||| IN
1  ||| S:23323 E:23325 ||| CD
hr  ||| S:23325 E:23338 ||| CD
each ||| S:23338 E:23342 ||| DT
,  ||| S:23342 E:23344 ||| ,
with  ||| S:23344 E:23349 ||| IN
45  ||| S:23349 E:23352 ||| CD
min  ||| S:23352 E:23356 ||| FW
TTBS  ||| S:23356 E:23361 ||| FW
washes ||| S:23361 E:23367 ||| FW
,  ||| S:23367 E:23369 ||| ,
and  ||| S:23369 E:23373 ||| CC
developed  ||| S:23373 E:23383 ||| VBN
in  ||| S:23383 E:23386 ||| IN
DAB ||| S:23386 E:23389 ||| NNP
/ ||| S:23389 E:23390 ||| NNP
Urea  ||| S:23390 E:23405 ||| NNP
( ||| S:23405 E:23406 ||| -LRB-
BioRad ||| S:23406 E:23412 ||| NNP
) ||| S:23412 E:23413 ||| -RRB-
.  ||| S:23413 E:23443 ||| .
Surface  ||| S:23443 E:23451 ||| NN
plasmon  ||| S:23451 E:23459 ||| NN
resonance  ||| S:23459 E:23469 ||| NN
with  ||| S:23469 E:23474 ||| IN
purified  ||| S:23474 E:23483 ||| FW
midgut  ||| S:23483 E:23500 ||| FW
receptors  ||| S:23500 E:23531 ||| FW
B.  ||| S:23531 E:23534 ||| FW
mori  ||| S:23534 E:23539 ||| FW
APN  ||| S:23539 E:23543 ||| NNP
and  ||| S:23543 E:23547 ||| CC
cadherin  ||| S:23547 E:23556 ||| NNS
were  ||| S:23556 E:23571 ||| VBD
immobilized  ||| S:23571 E:23583 ||| VBN
on  ||| S:23583 E:23586 ||| IN
a  ||| S:23586 E:23588 ||| DT
CM5  ||| S:23588 E:23592 ||| JJ
sensor  ||| S:23592 E:23599 ||| JJ
chip  ||| S:23599 E:23604 ||| NN
by  ||| S:23604 E:23607 ||| IN
the  ||| S:23607 E:23611 ||| DT
amine-coupling  ||| S:23611 E:23636 ||| JJ
method  ||| S:23636 E:23643 ||| NN
( ||| S:23643 E:23644 ||| -LRB-
Biacore  ||| S:23644 E:23652 ||| NNP
AB ||| S:23652 E:23654 ||| NNP
) ||| S:23654 E:23655 ||| -RRB-
.  ||| S:23655 E:23657 ||| .
Receptors  ||| S:23657 E:23667 ||| NNP
were  ||| S:23667 E:23672 ||| VBD
diluted  ||| S:23672 E:23680 ||| VBN
into  ||| S:23680 E:23685 ||| IN
ammonium  ||| S:23685 E:23704 ||| JJ
acetate ||| S:23704 E:23711 ||| NN
,  ||| S:23711 E:23713 ||| ,
pH  ||| S:23713 E:23716 ||| JJ
4.2  ||| S:23716 E:23720 ||| CD
prior  ||| S:23720 E:23726 ||| JJ
to  ||| S:23726 E:23729 ||| TO
immobilization ||| S:23729 E:23743 ||| VB
.  ||| S:23743 E:23745 ||| .
An  ||| S:23745 E:23748 ||| DT
HBS  ||| S:23748 E:23752 ||| NNP
( ||| S:23752 E:23753 ||| -LRB-
pH  ||| S:23753 E:23756 ||| NNP
7.4 ||| S:23756 E:23759 ||| CD
)  ||| S:23759 E:23771 ||| -RRB-
buffer  ||| S:23771 E:23778 ||| NN
flow  ||| S:23778 E:23783 ||| NN
rate  ||| S:23783 E:23788 ||| NN
of  ||| S:23788 E:23791 ||| IN
50  ||| S:23791 E:23794 ||| CD
μl ||| S:23794 E:23796 ||| CD
/ ||| S:23796 E:23797 ||| CD
min  ||| S:23797 E:23801 ||| NNS
was  ||| S:23801 E:23805 ||| VBD
used  ||| S:23805 E:23810 ||| VBN
for  ||| S:23810 E:23814 ||| IN
all  ||| S:23814 E:23828 ||| DT
injections ||| S:23828 E:23838 ||| NNS
.  ||| S:23838 E:23840 ||| .
Randomized  ||| S:23840 E:23851 ||| JJ
toxin  ||| S:23851 E:23857 ||| NN
concentrations  ||| S:23857 E:23872 ||| NNS
varying  ||| S:23872 E:23880 ||| VBG
from  ||| S:23880 E:23895 ||| IN
100  ||| S:23895 E:23899 ||| CD
nM  ||| S:23899 E:23902 ||| JJ
to  ||| S:23902 E:23905 ||| TO
1000  ||| S:23905 E:23910 ||| CD
nM  ||| S:23910 E:23913 ||| NN
were  ||| S:23913 E:23918 ||| VBD
injected  ||| S:23918 E:23927 ||| VBN
( ||| S:23927 E:23928 ||| -LRB-
110  ||| S:23928 E:23932 ||| CD
μl ||| S:23932 E:23934 ||| CD
)  ||| S:23934 E:23936 ||| -RRB-
over  ||| S:23936 E:23941 ||| IN
the  ||| S:23941 E:23955 ||| DT
receptor  ||| S:23955 E:23964 ||| NN
surfaces ||| S:23964 E:23972 ||| NN
.  ||| S:23972 E:23974 ||| .
Surfaces  ||| S:23974 E:23983 ||| NNP
were  ||| S:23983 E:23988 ||| VBD
regenerated  ||| S:23988 E:24000 ||| VBN
with  ||| S:24000 E:24005 ||| IN
6  ||| S:24005 E:24007 ||| CD
μl  ||| S:24007 E:24020 ||| JJ
pulses  ||| S:24020 E:24027 ||| NN
of  ||| S:24027 E:24030 ||| IN
10  ||| S:24030 E:24033 ||| CD
mM  ||| S:24033 E:24036 ||| JJ
NaOH ||| S:24036 E:24040 ||| NN
,  ||| S:24040 E:24042 ||| ,
250  ||| S:24042 E:24046 ||| CD
μM  ||| S:24046 E:24049 ||| JJ
ethylene  ||| S:24049 E:24058 ||| NN
glycol ||| S:24058 E:24064 ||| NN
,  ||| S:24064 E:24066 ||| ,
pH  ||| S:24066 E:24069 ||| JJ
11.0  ||| S:24069 E:24074 ||| CD
at  ||| S:24074 E:24087 ||| IN
100  ||| S:24087 E:24091 ||| CD
μl ||| S:24091 E:24093 ||| CD
/ ||| S:24093 E:24094 ||| CD
min ||| S:24094 E:24097 ||| NNS
.  ||| S:24097 E:24099 ||| .
Signal  ||| S:24099 E:24106 ||| NN
responses  ||| S:24106 E:24116 ||| NNS
from  ||| S:24116 E:24121 ||| IN
a  ||| S:24121 E:24123 ||| DT
blank  ||| S:24123 E:24129 ||| JJ
flowcell  ||| S:24129 E:24148 ||| NNS
containing  ||| S:24148 E:24159 ||| VBG
ethanolamine  ||| S:24159 E:24172 ||| NN
as  ||| S:24172 E:24175 ||| IN
a  ||| S:24175 E:24177 ||| DT
blocking  ||| S:24177 E:24186 ||| JJ
agent  ||| S:24186 E:24192 ||| NN
were  ||| S:24192 E:24207 ||| VBD
subtracted  ||| S:24207 E:24218 ||| VBN
from  ||| S:24218 E:24223 ||| IN
all  ||| S:24223 E:24227 ||| DT
response  ||| S:24227 E:24236 ||| NN
curves  ||| S:24236 E:24243 ||| NNS
and  ||| S:24243 E:24247 ||| CC
data  ||| S:24247 E:24252 ||| NNS
were  ||| S:24252 E:24257 ||| VBD
fitted  ||| S:24257 E:24274 ||| VBN
using  ||| S:24274 E:24280 ||| VBG
BIAevaluation  ||| S:24280 E:24294 ||| JJ
3.0 ||| S:24294 E:24297 ||| CD
.  ||| S:24297 E:24299 ||| .
The  ||| S:24299 E:24303 ||| DT
curves  ||| S:24303 E:24310 ||| NN
were  ||| S:24310 E:24315 ||| VBD
fit  ||| S:24315 E:24319 ||| VBN
to  ||| S:24319 E:24322 ||| TO
a  ||| S:24322 E:24324 ||| DT
simple  ||| S:24324 E:24341 ||| JJ
1 ||| S:24341 E:24342 ||| CD
: ||| S:24342 E:24343 ||| :
1  ||| S:24343 E:24345 ||| CD
Langmuir  ||| S:24345 E:24354 ||| JJ
binding  ||| S:24354 E:24362 ||| JJ
model  ||| S:24362 E:24368 ||| NN
to  ||| S:24368 E:24371 ||| TO
obtain  ||| S:24371 E:24378 ||| VB
apparent  ||| S:24378 E:24387 ||| JJ
rate  ||| S:24387 E:24402 ||| NN
constants  ||| S:24402 E:24412 ||| NNS
( ||| S:24412 E:24413 ||| -LRB-
A  ||| S:24413 E:24415 ||| DT
+  ||| S:24415 E:24417 ||| NNP
B  ||| S:24417 E:24419 ||| NNP
↔  ||| S:24419 E:24421 ||| NNP
AB ||| S:24421 E:24423 ||| NNP
) ||| S:24423 E:24424 ||| -RRB-
.  ||| S:24424 E:24457 ||| .
List  ||| S:24457 E:24462 ||| NN
of  ||| S:24462 E:24465 ||| IN
abbreviations  ||| S:24465 E:24487 ||| JJ
Bt ||| S:24487 E:24489 ||| NNP
,  ||| S:24489 E:24500 ||| ,
Bacillus  ||| S:24500 E:24509 ||| NN
thuringiensis  ||| S:24509 E:24523 ||| NNS
;  ||| S:24523 E:24525 ||| :
APN ||| S:24525 E:24528 ||| NNP
,  ||| S:24528 E:24538 ||| ,
aminopeptidase  ||| S:24538 E:24553 ||| VBG
N ||| S:24553 E:24554 ||| NNP
;  ||| S:24554 E:24556 ||| :
GPI ||| S:24556 E:24559 ||| NNP
,  ||| S:24559 E:24561 ||| ,
glycosyl-phosphatidylinositol ||| S:24561 E:24590 ||| JJ
;  ||| S:24590 E:24592 ||| :
BBMV ||| S:24592 E:24596 ||| NNP
,  ||| S:24596 E:24606 ||| ,
brush  ||| S:24606 E:24612 ||| FW
border  ||| S:24612 E:24619 ||| FW
membrane  ||| S:24619 E:24628 ||| FW
vesicles ||| S:24628 E:24636 ||| FW
;  ||| S:24636 E:24638 ||| :
LpNA ||| S:24638 E:24642 ||| NNP
,  ||| S:24642 E:24652 ||| ,
leucine-p-nitroanilide ||| S:24652 E:24674 ||| JJ
;  ||| S:24674 E:24676 ||| :
PIPLC ||| S:24676 E:24681 ||| NNP
,  ||| S:24681 E:24691 ||| ,
phosphatidylinositol-specific  ||| S:24691 E:24721 ||| JJ
phospholipase  ||| S:24721 E:24735 ||| JJ
C ||| S:24735 E:24736 ||| NNP
;  ||| S:24736 E:24738 ||| :
HBS ||| S:24738 E:24741 ||| NNP
,  ||| S:24741 E:24751 ||| ,
Hepes-buffered  ||| S:24751 E:24766 ||| JJ
saline ||| S:24766 E:24772 ||| NN
;  ||| S:24772 E:24774 ||| :
SPR ||| S:24774 E:24777 ||| NNP
,  ||| S:24777 E:24779 ||| ,
surface  ||| S:24779 E:24787 ||| FW
plasmon  ||| S:24787 E:24795 ||| FW
resonance  ||| S:24795 E:24820 ||| FW
